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Abstract 
OBJECTIVE: This meta-analysis aimed to determine the overall effect that psychotherapy 
has on anxiety disorders and to determine what moderates that effect.  Studies were grouped 
by type (efficacy or effectiveness) and grouped by analysis type (completer or intent-to-treat). 
METHOD: Medline was searched for articles published between 2011 and 2014 that related 
to the treatment of anxiety disorders.  An initial search revealed 8056 articles.  Of these, 99 
articles met inclusion criteria and were included in the final analyses. 
RESULTS: Overall, manualised psychotherapy outperformed control conditions. In general, 
psychotherapy for anxiety disorders had a large effect.  This effect appeared to be moderated 
by the use or lack of use of exposure techniques, with greater effects if exposure was used.  
This finding held particularly true for the treatment of post-traumatic stress disorder. 
CONCLUSION: Psychotherapies for anxiety disorders are both efficacious and effective.  
Exposure techniques enhance the effect of therapies.  Future research work is required to 
determine what else moderates the effect of such therapies.  
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The role of exposure in treatment of anxiety disorders: A meta-analysis 
 Anxiety disorders are amongst the most prevalent mental health issues in the world 
(Kadri, Agoub, El Gnaoui, Berrada, & Moussaoui, 2007; Kessler, Aguilar-Gaxiola, Alonso, 
Chatterji, Lee, Ormel, Üstün, & Wang, 2009; Kessler, Berglund, Demler, Jin, Merikangas, & 
Walters, 2005; Sartorius, Üstün, Lecrubier, & Wittchen, 1996).  A series of treatments from 
the cognitive behavioural therapy (CBT) paradigm have been shown to be efficacious in the 
treatment of anxiety disorders (e.g., Bradley, Greene, Russ, Dutra, & Westen, 2005; Eddy, 
Dutra, Bradley, & Westen, 2004; Fedoroff & Taylor, 2001; Hofmann & Smits, 2008; Norton 
& Price, 2007; Otto, Pollack, & Maki 2000; Westen & Morrison, 2001).  For example, in 
efficacy studies, Bradley et al. (2005) report a recovery rate of 67% for patients with post-
traumatic stress disorder (PTSD) who complete treatment, while Butler, Chapman, Forman, 
and Beck (2006) report 58% of clients showing clinically significant improvement after 
completing treatment for generalized anxiety disorder (GAD).  
 Exposure techniques are amongst the most powerful techniques for treating anxiety 
disorders from the CBT paradigm (Barlow, 2002; Minekla & Thomas, 1999).  For example, 
interoceptive exposure is the most efficacious method for reducing distress from panic attacks 
(Craske & Barlow, 2007), and Öst (1989) has shown that one-session exposure is efficacious 
in the treatment of specific/simple phobias.  Prolonged exposure and eye-movement 
desensitization reprocessing (EMDR) both use imaginal exposure, and are considered to be 
the most efficacious treatments for PTSD (Foa, Dancu, Hembree, Jaycox, Meadows, & 
Street, 1999; Foa, Hembree, Cahill, Rauch, Riggs, Feeny, & Yadin, 2005; Ironson, Freund, 
Strauss, & Williams, 2002; Lee, Gavriel, Drummond, Richards, & Greenwald, 2002; Resick, 
Nishith, Weaver, Astin, & Feuer, 2002).  
 The findings derived from efficacy studies are not always matched by results in the 
everyday practice.  In such settings, most clients do not improve, but rather show no change 
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after therapy (Chiver et al., 2001; Hansen, Lambert, & Forman, 2002; Schindler, Hiller, and 
Witthöft, 2011; Westbrook & Kirk, 2005; 2007).  It is not clear whether these lower levels of 
everyday practice outcomes are a product of the different setting, or of failure to use the 
evidence-based treatment appropriately.  It is crucial to consider whether therapies for 
anxiety disorders can have the same impact in real-life settings if the therapy is conducted 
appropriately.  Therefore, the key comparison is between highly controlled efficacy studies 
and real-world effectiveness studies, rather than comparing efficacy studies with routine 
practice. 
 A potential cause of the difference between efficacy studies and real-world 
effectiveness studies might be the underutilization of exposure techniques.  One of the most 
often cited reasons that exposure is not used is clinicians assume that it will not work in real-
world clinical settings (Becker, Zayfert, & Anderson, 2004; Feeney, Hembree, & Zoellner, 
2003; Olatunji, Deacon, & Abramowitz, 2009).  However, other researchers (Feeney et al., 
2003; Koch, Gloster, & Waller, 2007; Levita, Salas Duhne, Girling, & Waller, 2016) have 
posited that exposure might be underutilized due to the therapists’ own levels of anxiety 
about causing distress to the patient.  
 While efficacy studies in the form of randomized controlled trials (RCTs) have 
traditionally been used to set the standard for clinicians to achieve, effectiveness studies have 
been viewed as being a more accurate representation of what is achievable in ‘real-world’ 
settings (Rush, 2009).  Therefore, this meta-analysis will examine both efficacy and 
effectiveness studies to compare the impact of the relevant therapies on anxiety disorders. 
However, it is important to note that effectiveness studies are not truly analogous to actuarial 
data from routine practice.  Effectiveness studies are only a closer representation of routine 
practice as compared to RCTs.  
Another criticism of RCTs was that they typically have used completer analyses (CA) 
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only and had not used intent-to-treat analyses (ITT). The issue is that CA is not reflective of 
the real-world, whereas ITT analyses are more reflective of the real-world and less biased 
(Gupta, 2011; Hollis & Campbell, 1999; Schell, McBridge, Gennings, & Koch, 2001).  In 
many recent RCTs both CA and ITT analyses are provided. Therefore, in addition to 
considering efficacy (in RCT studies) versus effectiveness, this meta-analysis also will 
compare CA and ITT analyses.  Finally, while it is important to make direct comparison 
between efficacy and effectiveness studies, it is equally important to consider whether the 
findings of each are affected by potential moderator factors (e.g., diagnosis; type of therapy; 
the presence or absence of key therapy elements; therapeutic alliance).   
 This study aims to replicate previous literature (that addressed the efficacy and 
effectiveness of treatments for anxiety disorders), by determining the overall efficacy and 
effectiveness of psychological interventions for anxiety disorders, focusing on CBT based 
interventions.  The second aim is to extend the previous literature by determining what 
moderated treatment outcome.  If a particular component, for example exposure techniques, 
positively affects outcomes then when considering therapist drift, it is important to make sure 
these techniques are employed.  For each of these aims, the impact of both study type 
(efficacy and effectiveness) and analysis type (CA and ITT) will be assessed.  The third aim 
of this study is to update the list of empirically supported treatments (ESTs) using Chambless 
and Hollon’s (1998) criteria. 
Methods 
Selection criteria 
 Inclusion criteria differed according to whether the study came from a controlled 
highly controlled setting (i.e., efficacy studies) or from an uncontrolled clinical setting/real-
world setting (i.e., effectiveness studies).  The differences in inclusion criteria were kept as 
minimal as possible to ensure comparability across both study types.  All studies were in 
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English and published between 2011 and February 2014, so that research could be completed 
during the course of a PhD program.  These dates were used for convenience given the size of 
the literature.  The end (14 February 2014) was selected as it was the date on which the 
identification phase started.  To the knowledge of the author of this dissertation, no other 
studies have previously explored moderators in the treatment of anxiety disorders like this 
one has. Therefore, the start date was selected to ensure an adequate sample size that would 
provide meaningful results. 
 The inclusion criteria were as follows: (a) a treatment study of a clearly specified and 
diagnosed anxiety disorder;  (b) use of a treatment manual or set protocol (for efficacy 
studies, this only applied to the experimental conditions); (c) that the treatment employed at 
least psychological intervention (pharmacological only studies were excluded whereas 
studies using both psychology and pharmacological approaches were included); (d) in a series 
of single-case studies, a sample size of 10 or greater was required; (e) there was a 
standardized measure of anxiety symptoms at pre-test and post-test; (f) the study included the 
data necessary to calculate effect size (i.e., mean and standard deviation); and (g) in efficacy 
studies, the experimental condition had to either be compared to a wait-list control, treatment 
as usual (TAU) control, minimal/no contract control, healthy control, a control with the active 
treatment component missing, or another empirically supported treatment.  Any studies not 
fulfilling these requirements were not included in analysis. 
 These criteria were used to help find a larger heterogeneous sample.  By having a 
large sample like heterogenous sample, more moderation analyses would be possible. While 
the samples may be heterogenous (e.g., inpatient and outpatient, different disorders), there is 
overlap in protocols used to treat many of these various groups. Despite the attempt to get a 
richer sample to work with, there were not enough data to analyse all the moderators of 
interest. 
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 Exclusion criteria. Studies without standardized measures were not included, as 
standardized measures allow for a more accurate and reliable way to compare included 
groups than other methods (e.g., clinical judgement; Dawes, Faust, & Meehl, 1989).  Any 
articles without English translation were also excluded.  If the article was only available 
behind a paywall, the article was not included (see eligibility below).  Any study not 
including psychotherapy (e.g., pharmacotherapy only) was not included.  Finally, any studies 
where the type of psychotherapy was left undefined were not included.  
 If two related studies used the same dataset (e.g., a follow-up study that included the 
original dataset or an extension on the original study), the more recent of the two datasets 
were used.  In this case, no articles met this criterion. A few studies were follow-up studies 
but the original studies were from prior to 2011.  If the datasets were the same but the focus 
of the article was different (outcome of services versus cost of services), only the article 
originally coded into the study was included (n = 2). 
 Missing data or errors related to essential data (i.e., mean, SD, N) resulted in that 
study/condition not being coded.  If an error was identified in the data in the original paper 
(e.g., number of participants was greater at the end of the study than at the start), the data 
were not included.  
 In cases where multiple clinical populations (e.g., PTSD and OCD) were analysed 
separately, the data were coded separately.  However, in cases where multiple clinical 
populations were analysed as one group (i.e., all participants with an anxiety disorder 
collapsed into a single group), the data were not included.  Despite this meta-analysis 
considering a variety of anxiety disorders, the authors attempted to keep homogenous 
groupings (i.e., one disorder, one outcome).  In cases where comorbid diagnoses were 
required by the study for inclusion, the comorbid disorder was noted (see summary of study 
characteristics below). 
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 Finally, if there was an issue with the reporting of non-essential data (i.e., sample size 
not reported at follow-up; measure at follow-up changed, and not used elsewhere in the 
study; statistics clearly inaccurate), these data were not used but any useable non-essential 
data were included. 
Moderator analyses 
 One of the primary moderators of interest was the difference between the two study 
types (i.e., efficacy and effectiveness).  Efficacy and effectiveness studies were further 
divided into two more groups based on the analysis type used (i.e., CA or ITT).  There were 
five other moderators of interest: the use of exposure; the anxiety disorder treated; length of 
treatment; therapeutic alliance; and the year of publication (to explore if therapies or the 
application of therapy became more effective in the treatment of anxiety disorders).  Where 
possible, these moderators were examined together (e.g., efficacy studies for PTSD with 
exposure using ITT analysis versus efficacy studies for PTSD without exposure using ITT). 
Search strategies 
 Initial search. Figure 1 shows the process of identification and selection of articles.  
Medline, via OVID, was searched for articles published between February 14, 2014 (day of 
initial search) and January 1, 2011.  The search terms (see appendix A) were divided into 
three categories: disorder terms, therapy terms, and result terms.  Due to the difference 
between American English and British English, wildcards were not always feasible.  
Therefore, to account for the differences in spelling, multiple spellings were used were 
appropriate.  Within each category (e.g., disorder terms), ‘OR’ was placed between search 
term (e.g., ‘anxiety OR anxiety disorder OR generalized anxiety disorder’).  Between each 
category, ‘AND’ was placed.  This was to ensure that the results had at least one keyword 
from each category. 
 Screening. The initial screening reviewed the title and abstracts of all articles 
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returned by the initial search.  Any study that appeared to be relevant and/or met inclusion 
criteria was included for the next step. Any article excluded (n = 7276) at this point was due 
to the subject of the paper either not relating the topic, the paper being a proposed study 
protocol, or meeting exclusion criteria based on information provided in the abstract.  Many 
of these studies (exact amount not recorded) related to medical only treatments for anxiety 
disorders, medical issues (e.g., COPD), anxiety around sexual health related to a medical 
issue (e.g., pelvic floor collapse and vaginismus) or anxiety around medical procedures (e.g., 
oral surgery).  Considering the types of articles excluded and the publication bias analyses 
(see below), it is unlikely that these articles would or could have influenced the results of this 
study. 
 Eligibility. The next step was a full read of the article to determine eligibility.  If the 
database did not have a full text copy, other methods (i.e., Google Scholar, academia.org, 
researchgate.com, and personal websites) were used to locate the article if possible.  
Contacting authors was not undertaken, to avoid response bias (i.e., where authors of newer 
papers are more likely to respond).   
 Articles were examined at this stage to ensure all inclusion criteria and no exclusion 
criteria were met.  Any questions regarding eligibility were assessed and dealt with in this 
stage by the lead author (ZJP) and second author (GW).   
 Judges. The primary judge was the lead author (ZJP), a PhD student.  Another author 
(GW), a professor with 30 years of experience and supervisor to the first author, acted as a 
secondary judge and consulted with the primary judge when needed.  Another author 
(PGSD), a first-year doctor of clinical psychology student, completed ratings of papers to 
establish inter-rater reliability. 
_________________________ 
Insert figure 1 about here 
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_________________________ 
 
Coding procedures 
 The coding for control conditions for the analysis of controlled effect sizes was 
completed by PGSD.  All other coding was done by ZJP.  Checking of coding and 
mathematical procedures was conducted by the remaining author (JD), a professor of health 
management, and statistician with 18 years of experience in academic research. 
 Coding. Coding was completed using Microsoft Excel.  Randomized control trials 
(RCTs) had to be coded in twice - once for analysis of controlled effect sizes (see below), and 
again for analysis of uncontrolled effect sizes (see below).  Only in the former were control 
(i.e., non-psychotherapy) conditions coded.  
 The following was coded: author(s); year of publication; anxiety disorder treated (and 
any additional required disorder for inclusion in the selected study); inclusion criteria; 
exclusion criteria; use of exposure; study type; the mean and standard deviation at pre-test, 
post-test, and follow-up (if applicable) for CA and/or ITT analysis; measure used; sample 
size at post-test; sample size at follow-up; mean age in year with standard deviation; gender 
by percent female; ethnic group; length of treatment; working alliance; socioeconomic status; 
education; marital status; Critical Appraisal Skills Programme (CASP) ratings (see below);  
title; and any notes.  
 Assessment of quality. CASP rating systems were used to assess the quality of the 
studies included.  In the end, only the CASP Randomised Controlled Trial Checklist and 
CASP Cohort Study Checklist were used.  The former was used with all efficacy studies, and 
the latter with all effectiveness studies.   
 Of the 99 articles, 10 (10.1%) were chosen randomly by a random integer generator 
from random.org, and then reviewed.  All items, except item 8, on both versions of the CASP 
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were rescored on those 10 articles for comparison.  Item 8 (from both versions) was omitted 
as there was no possible answer other than what was initially reported.Fo 
 Missing data. No substitution of missing data was carried out.  For example, if an 
article had a follow-up but did not give enough information for the follow-up to be included 
in analysis, then only the pre-/post-test effect size was included. 
 Unclear data. In cases where multiple groups were reported as one group without 
distinction, the information was coded as ‘not clearly reported’.  This held true unless the 
combined data pertained to essential data (e.g., inclusion criteria; see above), in which case 
the article was not included. 
 
Data analysis 
 All analyses were done by hand using Microsoft Excel, unless stated otherwise.  To 
address the first aim of the study, both analyses of controlled and uncontrolled effect sizes 
were conducted (see below).  To address the second aim, both ANOVA analogues and meta-
regressions were conducted (see below).   
 Publication bias.  Three calculations were used to determine the scope and effect of 
publication bias.  First, an Egger’s Regression (Egger, Smith, Schneider, & Minder, 1997) 
was calculated, to determine the overall publication bias.  Due to issues with Egger’s 
Regression (see: Egger & Smith, 1998; Irwig, Macaskill, Berry, & Glasziou, 1998; Song, 
Khan, Dunnes, & Sutton, 2002; Van Enst, Ochodo, Scholten, Hooft, & Leeflang, 2014), Begg 
and Mazumdar’s (1994) rank correlation test was also calculated.  Finally, a Rosenthal’s 
Failsafe-N (Rosenthal, 1979) was calculated to determine how many trivial effects would 
have to be reported to reduce the overall effect size. 
 Analysis of controlled effect sizes. RCTs where at least one active treatment is 
compared to a control condition (e.g., TAU, waitlist, healthy control, no/minimal contact) 
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were included for this analysis.  In the cases where a study used two (or more) active 
treatments, these active treatments were not compared against each other.  
 All calculations for this analysis were derived from Field (2000), Ellis (2010), and 
Heges and Pigott (2004).  Effect size (d) was calculated as 
?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙−?̅?𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙
𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑
 where SDpooled 
was calculated using Cohen’s simplified formula, √
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2 + 𝑆𝐷𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙
2
2
.  This way, 
positive effect sizes indicate that the experimental condition outperformed the control 
condition, as lower scores indicated greater reduction of distress.  In this formula, the mean 
and standard deviation came from post-test for both the control and experimental group.  
Next dunbiased was calculated using the following formula: (1 −  
3
4(𝑁−2)−1
) 𝑑.  dunbiased was 
used here to control for the difference in sample sizes between the two conditions in each 
comparison.  Variance (?̂?𝑑
2) for controlled analysis was calculated thusly:  
𝑛𝑖
𝑒+𝑛𝑖
𝑐
𝑛𝑖
𝑒𝑛𝑖
𝑐 +
𝑑𝑖
2
2(𝑛𝑖
𝑒+𝑛𝑖
𝑐)
, 
where ne is the sample size of the experimental condition and nc is the sample size of the 
control group.  From there, an average effect size (𝑑+)was estimated using the formula: 
∑
𝑑
?̂?𝑑
2
∑
1
?̂?𝑑
2
.  
The estimate of standard deviation of the overall effect size (?̂?𝑑+) was calculated using: 
√(∑
1
?̂?𝑑
2)
−1
.  From there, the overall score was standardized to a z-distribution by dividing the 
overall effect by the estimate of the standard deviation.  Heterogeneity (Q) was tested by 
taking the sum of squared differences between each effect size (d) and the overall effect size 
(d+).  From this, a random-effects model (calculations below) was used to determine the 
overall effect size. 
 Standard error for the forest plots was calculated using the standard error of the effect 
size, and was calculated as follows: 𝑆𝐸(?̅?) =  
𝑑
√𝑑×𝑛
.  The calculations for the z-statistic are 
TREATMENT OF ANXIETY DISORDERS  13 
 
reported below. 
 Analysis of uncontrolled effect sizes. Arms of studies using TAU, waitlist, non-
manualized treatments, or controls other than active treatment were not included for analysis 
of uncontrolled effect sizes.  Only active treatments involving psychotherapy (with or without 
supplemental treatments) were included in this step.   
All calculations for this analysis come from Ellis (2010), Hedges et al. (2004), and Johnson 
and Eagly (2000).  Effect size was calculated as 
?̅?𝑝𝑟𝑒−?̅?𝑝𝑜𝑠𝑡
𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑
, where SDpooled was calculated 
using Cohen’s simplified formula, √
𝑆𝐷𝑝𝑟𝑒
2 + 𝑆𝐷𝑝𝑜𝑠𝑡
2
2
.  This way a positive effect size indicated a 
reduction in symptoms.  In analysis of effect size from pre-test to follow-up, the mean and 
standard deviation from pre-test and follow-up were used.  Similarly, in the analysis of 
maintenance, mean and standard deviation at from post-test and follow-up were used.  
 Variance (Vi) was calculated using the following formula 
4 (1+ 
𝑑𝑖
2
8
)
𝑛𝑖
 , where di is an 
individual study’s effect size and ni is an individual study’s sample size.  
 Homogeneity was tested by calculating a Q-statistic for each analysis, where 𝑄 =
∑ 𝑤(𝑑)2 −  
∑(𝑤𝑑)2
∑ 𝑤
, where w was the inverse of variance (1/vi).  It was expected, and found, 
that in most cases that the residual error was not normally distributed, or in other words, there 
was a significant level of heterogeneity (Q was greater than a critical chi-square value), and 
therefore a random-effects model was used.  
 A τ2 statistic was calculated using the following formula (Q-(K-1))/C, where K was 
the number of comparisons included and where C was the sum of squares of the study 
weights (w) from the fixed-effects model.  The random-effects study weights were calculated 
as: 𝑤∗ =
1
𝑉𝑖+ τ
2 .  Weighted effect sizes were therefore calculated as the product of w
* and 
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effect size (d). The overall mean effect size (?̅?∗) was calculated as:  
∑ 𝑤∗𝑑
∑ 𝑤∗
.  
Confidence intervals were calculated using effect size + (1.96 * standard error). Standard 
error for the overall sample was calculated by taking the square root of the overall variance, 
where overall variance was calculated using the following formula: 𝑣.
∗ =  
1
∑ 𝑤∗
.  
For all tables presented, unless stated otherwise, the unweighted effect sizes are reported. 
Standard error was calculated.  The standard error reported in the tables was calculated using 
the standard method.  
 To determine if there was truly an effect, the difference between the observed effect 
and no effect were calculated on a z-distribution.  The formula for which is: 
|?̅?∗−0|
𝑆𝐸?̅?
.  If a score 
was greater than 1.96 (or less than -1.96), then there was a significant effect.  If a score is not 
significant then it cannot be said that there was an effect.  
 Moderator analyses.  Formulas for the moderator analyses come from Hedges et al. 
(2004) and Johnson et al. (2000).  For four of the five moderator analyses, ANOVA 
analogues were computed by hand with a chi-square distribution, using a mixed-model 
methods.  
 Comparisons were made between study types (i.e., efficacy and effectiveness) but 
within analysis type (i.e., CA or ITT).  No comparisons were made within both types, as in 
some cases that would be using duplicate data where studies reported both ITT and CA 
results.  All studies were included for this analysis. 
 Regarding the effects of exposure, a minimum k of five was required within each 
group.  Data were grouped based on study type, then by analysis type, and then by exposure 
use (resulting in eight different combinations).  This was done for pre-/post-test effect size 
and for pre-test to follow-up effect sizes (resulting in a potential of 16 different cases). 
However, only 13 of the 16 groups meet the minimum k of five.  ANOVA analogues were 
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used to compare within study types (e.g., efficacy CA with exposure versus efficacy CA 
without exposure), across study types (e.g., efficacy CA with exposure versus effectiveness 
CA with exposure). Effectiveness ITT without exposure (k = 4 in pre-/post-test and k = 0 in 
pre-test to follow-up) and Effectiveness CA without exposure (k = 0 at pre-test to follow-up 
only) were not included. 
 Regarding disorders, a minimum k of five was expected within each group.  Initial 
analyses revealed that only three disorders would meet this criterion (social anxiety disorder 
(SAD), PTSD, and OCD).  They were grouped as described above, first by study type, then 
by analysis type, then by disorder type.  ANOVA analogues were used to determine if there 
was a difference in effect size across each study type but within each analysis type for each 
disorder (e.g., efficacy CA of OCD studies versus effectiveness CA of OCD studies).  
Regarding exposure and disorder, where possible the groupings of disorders were then 
subdivided between those with exposure and those without exposure.  Only PTSD offered 
enough data to compare the effects of exposure between and within study types.  The 
following disorders did not offer enough datasets to conduct moderator analysis: generalized 
anxiety disorder (GAD), agoraphobia, panic disorder, and simple phobia. 
 Analysis on year of publication was conducted even if a set of studies from one year 
had a k of less than five and the other years had met minimal amount (this occurs in the 
analysis of effectiveness studies with CA).  All combinations, except effectiveness ITT, were 
compared in this moderator analysis.  Over the course of years included, there were on 
average 1.5 (range 0-3) studies a year that reported effectiveness ITT. 
 Length of treatment was grouped into a range as follows: 1-5, 6-10, 11-15, and 16+ 
sessions.  Grouping was based on the easiest manageable chunks that would allow for 
comparison to findings from studies on the dose-redose effect of psychological interventions 
(e.g., Hansen et al., 2002).  Studies were divided similarly the other moderators, first by study 
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type, then analysis, then into the length of treatment groups.  ANOVA analogues were used 
to determine the effect of treatment length on the effect size of treatment.  No moderator 
analysis was run on effectiveness studies using ITT analysis, as there was only one source 
(11-15 sessions) that had a K > 5.  
 Finally, the fifth moderator (therapeutic alliance) was examined using a meta-
regression, using SPSS version 21 to conduct the initial regression.  For this, the raw effect 
size (Cohen’s d), the scores on the therapeutic alliance measure, and w* were coded into 
SPSS and run through a weighted linear regression with w* acting as the case weight.  The 
results were then modified in Excel to find the standard deviation of the slope and the z-score.  
Standard deviation of the slope was calculated by 
𝑆𝐸
√𝑀𝑆𝐸
 where SE is the standard error of the 
slope provided by SPSS and MSE is the mean square error of the overall model as provided 
by SPSS. 
 The I2 index in all cases was 0; in no cases was the Q-statistic greater than the K-1 in 
any analyses.   
 Determining empirical support.  This meta-analysis used a slightly stricter version 
of the criteria set forth by Chambless and Hollon (1998) for determining which treatments are 
empirically supported (aim 3).  The reason for using this stricter set of criteria is that this 
meta-analysis examined only experimental versus control conditions in the analysis of 
controlled effect sizes.  This means that comparisons between active treatment conditions, 
which are allowed under Chambless and Hollon's (1998) criteria, were not considered in this 
analysis.  Furthermore, this meta-analysis only reports on studies published during the target 
years (2011-2014), independent from all other research.  
Treatments were grouped into two categories, as suggested in Chambless and 
Hollon’s paper: ‘efficacious’ or ‘possibly efficacious’.  Anything not listed in either category 
was treated as having no empirical support.  To be included in this analysis, RCTs needed 30 
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participants per condition.  All other criteria from Chambless and Hollon were met by the 
inclusion criteria for this meta-analysis (e.g., must be manualised).  To be considered 
‘efficacious’, a study had to be replicated by an independent lab and meet all the criteria set 
by Chambless and Hollon.   
Results 
Summary of study characteristics 
 A total of 99 studies were included in the main analyses, of which 61 were efficacy 
studies, reporting 108 active treatment conditions and 40 control conditions.  The remaining 
38 studies were effectiveness studies, reporting 51 active treatment conditions. Thus, a total 
of 159 active treatment conditions were included in the main analyses.  
 Table 1 presents the overview of efficacy studies included in the main analyses.  Of 
these studies, 66 conditions reported using exposure techniques, and 42 conditions did not 
use exposure.  In one condition of one study (Andrews et al., 2011), it was not clear if 
exposure was utilized and referenced a text unavailable to the authors of this meta-analysis.  
As it was not expressly stated, it was assumed this active treatment condition in this study did 
not use exposure.  The decision not to contact the author steams from the discussion not to 
contact authors during the selection process (see above).  The following disorders are 
represented by this sample of studies: Agoraphobia with panic disorder (k = 2); GAD (k = 7); 
obsessive-compulsive disorder (OCD; k = 25)1; panic disorder (k = 5); PTSD (k = 27)2; social 
anxiety disorder (SAD; k = 32)3; and simple/specific phobia (k = 10)4.  
---------- 
Insert Table 1 about here 
                                                 
1 Two of these conditions were comorbid OCD with an autism spectrum disorder. 
2 Two of these conditions were comorbid PTSD with alcohol use disorder; another two conditions recruited 
from a treatment resistant PTSD sample. 
3 One of these conditions was comorbid SAD with a personality disorder. 
4 Four in these conditions were flying phobias; four were acrophobia; and two were snake phobias. 
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---------- 
 Table 2 presents the overview of effectiveness studies included in the main analyses.  
Of these studies (K = 51), 43 conditions reported using exposure techniques; the remaining 
eight conditions did not use exposure.  The following disorders are represented by this 
sample of studies: GAD (k = 6); OCD (k = 11)5; panic disorder (k = 5)6; PTSD (k = 23)7; 
social anxiety disorder (k = 6)8. 
---------- 
Insert Table 2 about here 
---------- 
 
Summary of quality assurance 
 Tables 3 and 4 present the quality ratings for efficacy and effectiveness studies, 
respectively.  Follow-up was reported in 84 (77.06%) of the conditions in efficacy studies.  
However, one study could not be used, as it did not report the follow-up sample size (Ma et 
al., 2013).  Regarding effectiveness studies, only 15 (29.41%) of conditions reported a 
follow-up.  All reported follow-up data were useable.  
---------- 
Insert Tables 3 and 4 about here 
---------- 
 Inter-rater reliability.  The overall inter-rater reliability score was 76%.  There was 
substantial agreement between the two raters - Cohen’s kweighted = .71 (95% CI .57 to .85).  
Publication bias 
                                                 
5 One of these conditions focused on hoarding. 
6 Two of these conditions presented comorbid cases, one of panic disorder with irritable bowel syndrome and 
the other of panic disorder with a personality disorder. 
7 One condition was comorbid PTSD with major depressive disorder; two conditions were comorbid PTSD with 
traumatic brain injury. 
8 One condition was comorbid SAD with any depressive disorder. 
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 Regarding efficacy CA studies, visual inspection of the funnel plot, presented in 
figure 2(a), indicated possible publication bias, this was confirmed by an Egger’s Regression 
(pre- vs. post-treatment): (B0) = 9.24, 95% CI = [4.86 – 13.61], p < .001.  This was 
confirmed by Begg-Mazumdar’s rank correlation, τa = 0.31, p = .002.  However, the 
necessary number of unpublished null trials to reduce the obtained mean effect size to trivial 
levels would be 2865.  This suggests that there probably is not a file-drawer problem.  
 Figure 2(b) presents the funnel plot for publication bias for efficacy studies using ITT 
analysis, indicating potential publication bias.  Again, this was confirmed by a significant 
Egger’s Regression (pre- vs. post-treatment): (B0) = 11.06, 95% CI = [8.84 – 13.29], p < 
.001.  This was confirmed by a Begg-Mazumdar’s rank correlation, τa = 0.4, p < .001.  
However, the necessary numbers of unpublished null trials to reduce the obtained mean effect 
size to trivial levels would be 7833.  This suggests there probably is not a file-drawer 
problem.  
 Figure 2(c) presents the funnel plot for publication bias for effectiveness studies using 
CA, indicating potential publication bias.  This was confirmed by a significant Egger’s 
Regression (pre- vs. post-treatment): (B0) = 5.09, 95% CI = [2.59 – 7.60]. p < .001.  This was 
also confirmed by a Begg-Mazumdar’s rank correlation, τa = 0.23, p = .019.  However, the 
necessary number of unpublished null trials to reduce the obtained mean effect size to trivial 
levels would be 6106.  This suggests there probably is not a file-drawer problem. 
 Figure 2(d) presents the funnel plot for publication bias for effectiveness studies using 
ITT analysis, indicating potential publication bias.  This bias was confirmed by a significant 
Egger’s Regression (pre- vs. post-treatment): (B0) = 15.42, 95% CI = [10.12 – 20.72], p < 
.001.  This was also confirmed by a Begg-Mazumdar’s rank correlation, though given the low 
K this result should be interrupted with caution, τa = 0.3, p = .037.  However, the necessary 
number of unpublished null trials to reduce the obtained mean effect size to trivial levels 
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would be 713.  Again, this suggests there probably is not a file-drawer problem. 
---------- 
Insert Figure 2 about here 
---------- 
 
Analysis of controlled effect sizes 
 Figures 3 and 4 present the forest plots for the analysis of controlled effect sizes for 
CA and ITT analyses respectively.  In all but two cases (in the ITT set), the experimental 
condition performed better than the control condition.  
---------- 
Insert Figures 3 and 4 about here 
---------- 
Analysis of uncontrolled effect sizes. 
 Pre-/post-test.  Table 5 presents the analyses for uncontrolled effect sizes from pre- 
to post-test.  Overall, all analyses yielded significant results, p < .001 in all cases.  The mean 
effect sizes were all large (> 1.15 in all cases).  
 Pre-test to follow-up.  Table 5 presents the findings for the uncontrolled effect sizes 
from post-test to follow-up.  Overall, all analyses yielded significant results, p < .001 in all 
cases.  The mean effect sizes were all large (> 1.4 in all case).  
 Maintenance (post-test to follow-up).  Table 5 also presents the findings for the 
analysis of uncontrolled effect sizes from post-test to follow-up (i.e., maintenance).  Only 
efficacy studies had a significant effect; [Efficacy CA (?̅?∗= 0.23, p = .046) and Efficacy ITT 
(?̅?∗= 0.16, p = .003)].  Neither effectiveness analysis yielded significant results (p > .34 in 
both cases).  Therefore, there is support for a continued effect from therapies after completion 
of treatment in efficacy studies.  No such support exists for effectiveness studies.  
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---------- 
Insert Table 5 about here 
---------- 
Moderator analyses 
 Exposure use.  Table 6 reports the outcomes from the examination of exposure as a 
moderator.  Only in efficacy ITT studies was exposure a moderating variable in the outcome 
of therapy.  Studies with treatments using some form of exposure in efficacy ITT (?̅?∗= 1.39, 
SE = .1) out performed those treatments that did not use an exposure element, (?̅?∗= 0.96, SE 
=.1), p = .002.  
 Disorder.  The overall effects size for each disorder are presented in table 5. All 
primary analyses for disorder were significant and most had large effect sizes. 
 Regarding OCD, the only analyses possible (due to number of conditions available) 
were between study type and CA and the comparison between study types using CA and 
exposure techniques.  The results of which are reported in table 6.  In neither case was there a 
significant difference, p > .30 in both cases.  
 The results from the moderator analyses of PTSD are also presented in table 6.  
Again, exposure was found to be a moderating factor in the differences in effect size for 
efficacy ITT studies, where those who received exposure (?̅?∗= 1.43, SE = 0.15) had better 
outcome than those who did not receive exposure (?̅?∗= .94, SE = 0.18).  Overall, treatments 
for PTSD were found to have a large and significant effect size. 
 Regarding SAD, only analyses involving CA between study types and efficacy studies 
using ITT analyses with and without exposure could be conducted.  The results of which are 
presented in table 6.  Neither result was significant, p > .285 in both cases. 
 Length of treatment. Table 6 presents the findings for the moderator analyses of the 
length of treatment.  Length of treatment did not appear to moderate the effect size from pre- 
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to post-test. 
 Therapeutic Alliance.  A meta-regression examining therapeutic alliance’s 
association with effect size at end of treatment yielded a non-significant model F(1, 4) = 1.78, 
p = .275.  The meta-regression equation was also not significant, z = .34, p = .377. 
 Year of publication. Year of publication did not moderate the effect size at the end of 
treatment in any condition.  Table 6 presents the findings for each study and analysis type by 
year.  Table 6 also presents the only significant difference found, which was between efficacy 
and effectiveness studies with completer analyses published in the year 2011. 
---------- 
Insert Table 6 about here 
---------- 
Empirically supported treatments 
 Table 7 details which treatments met Chambless and Hollon’s (1998) criteria for 
empirically supported treatments, within the limitations outlined above.  Again, this analysis 
of  which treatments are empirically supported looks at the research collected for this meta-
analysis independent of all other research.  This means that a study listed as ‘possibly 
efficacious’ here might have been consider efficacious in the wider literature.  Some of the 
treatments in the ‘possibly efficacious’ group had been replicated, but the replications lacked 
a sufficient sample size, while others lacked any independent replication. 
 
---------- 
Insert Table 7 about here 
---------- 
Discussion 
 This was a meta-analysis of efficacy and effectiveness studies of the 
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psychotherapeutic treatment of anxiety disorders.  It included studies from a period of over 
three years.  In addition, it considered possible moderators, such as type of anxiety disorder, 
use or absence of an exposure therapy element, length of treatment, therapeutic alliance, and 
year of publication.  While the studies allowed firm conclusions regarding outcome by the 
end of treatment, it was noteworthy that the number of effectiveness studies with follow-up 
data was limited. 
 Overall, psychotherapy had a large effect size in the treatment of anxiety disorders.  
However, there was no overall difference between efficacy studies and effectiveness studies, 
indicating that the impact of psychotherapy is as positive in ‘real life’ settings as in highly 
controlled ‘lab’ settings.  Finally, patients whose therapy included an exposure element fared 
substantially better by the end of therapy than those who did not have any exposure element 
to their psychotherapy.  There were not enough studies to consider this difference within all 
individual disorders, but it is noteworthy that those patients with PTSD who received 
exposure did significantly better than those who did not receive exposure.  In contrast, there 
was no such difference for the treatment of SAD. 
 The findings of this meta-analysis are generally in line with what is reported in other 
meta-analyses (Abramowitz, 1996; Bisson, Ehler, Matthews, Pilling, Richard, & Turner, 
2007; Hofmann et al., 2008; Taylor, 1996; Van Etten & Taylor, 1998).  CBT performed 
better than most controls, as Hofmann et al. (2008) found.  This meta-analysis supports the 
findings of Bisson et al. (2007) and Van Etten et al. (1998), in that CBT and EMDR are 
efficacious treatments for PTSD.  It also concurs with the conclusion that exposure and 
response/ritual prevention (ERP) is highly efficacious in the treatment of OCD (Abramowitz, 
1996).  Finally, it shows no difference between CBT and treatments with an element of 
exposure for social anxiety disorder, as has previously been concluded (Feske & Chambless, 
1995).  There was no difference between effectiveness and efficacy studies, as would be 
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expected.  This lack of difference may be due to the inclusion criteria, or the lack of variance 
due to heterogeneity across the studies (as indicated by the I2 index being 0 in all cases); or 
issues related to the weighting, use of effect sizes, and or issues with meta-analytic methods 
in general (Ferguson, 2009; Hedges & Pigott, 2004). 
Clinical implications 
 Exposure was shown to be the only moderator in ITT analyses and in PTSD 
treatments.  No such effect was found in CA and with other disorders, though the likelihood 
of finding this effect might have been reduced by publication bias.  As ITT is a more accurate 
representation of what occurs in daily practice, these findings show that it is important for 
clinicians to consider the use of exposure techniques in treatment of anxiety and related 
disorders.   
 The data regarding the treatment of OCD indicate that CBT or ERP should be used.  
Considering PTSD, exposure had the most support, though both cognitive therapy (CT) and 
cognitive processing therapy may also work.  Considering SAD, CBT should be used as the 
frontline treatment, while both mindfulness and acceptance based therapy and CT might also 
be effective. 
Research implications 
Future studies should explore the difference between CA and ITT with regards to the 
use of exposure.  As this meta-analysis revealed that the effect of exposure only moderated 
outcomes in ITT analysis and not CA, the question as to why remains.  It is quite possible 
that the sample size was inadequate for the CA to show a moderation effect, or that as 
compared to ITT everyone in the CA had exposure but some in the ITT sample did not as 
they left therapy prior to starting exposure. 
 Only three studies reported on therapeutic alliance.  Of those, only two (k = 5) were 
measured in such a way that would have allowed for them to be assessed in a meta-
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regression.  Therefore, more studies need to include some measure of therapeutic alliance if it 
is to be tested for it importance.  The same is true of quality of life.  In future meta-analyses, 
the relationship between both variables (therapeutic alliance and quality of life) and clinical 
improvement should be assessed. 
 A further issue is that several studies could not be included in this analysis because 
they collapsed clinical groups (e.g., PTSD and OCD) into one group, and did not give 
diagnosis- and condition-specific demographics.  Therefore, future researchers should 
consider reporting their findings by specific disorders and for the different experimental 
conditions (e.g., treatment A vs treatment B). 
Future meta-analyses that use Chambless and Hollon’s (1998) criteria to define 
studies as efficacious or partially efficacious should use a longer time frame, in order not to 
miss treatments that may be meet the criteria.  Similarly, as this meta-analysis assessed the 
publication dates and found no difference, future meta-analyses may instead want to compare 
first, second, and third wave therapies. 
This meta-analysis indicated that there was maintenance of treatment outcomes in 
efficacy studies but no such maintenance in effectiveness studies.  This can be an artefact of 
relatively few effectiveness studies having a follow-up as compared to efficacy studies.  The 
maths used in this study, should account for the difference in number of relevant articles, 
however, these techniques are not full-proof.  Therefore, the results should be interrupted 
with caution and future meta-analyses should assess the difference between maintenance 
effects across efficacy and effectiveness studies. In addition, future studies can also look at 
the difference in follow-ups between efficacy studies and effectiveness studies, similar to 
how studies have previously reviewed the different in the intervention portions of both types 
of studies.  
Limitations 
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This meta-analysis had many limitations.  First and foremost were the search criteria.  
The criteria used, in particular the third category (see Appendix A), meant that more therapies 
related to CBT or behavioural therapy would be returned.  This does not allow for an accurate 
analysis looking at the differences between various theoretical paradigms.  Other methods 
(e.g., psychodynamic, mindfulness-based) may have had more studies than what was 
represented here and may or may not have a greater effect than reported.  
Another limitation is the lack of routine care data.  If the primary question is how well 
do clinicians preform in the highly controlled settings versus routine care, the use of 
effectiveness studies and efficacy studies does not fully address this question.  However, 
there are very few published studies that used actuarial data from routine clinical work.  
Therefore, the lack of difference between efficacy and effectiveness may not reflect the 
difference between efficacy studies and the real-world. Alternatively, the result reported here 
may correctly reflect the lack of difference in efficacy and effectiveness studies but not 
address other issues within publication bias.  For examples, it is possible that only studies that 
showed a positive effect were published.  This means that studies with a trivial or null effect 
may have been missed in the analysis.  Therefore, publication bias may obscure the amount 
and case of trivial or null effects.  
 Considerin therapeutic alliance, while just enough arms of studies (k = 5) were 
present to conduct a meta-regression, these data only came from two studies.  Given the 
literatures support of therapeutic alliance being fundamental in the success of therapy, it is 
shocking that so few studies would include a measure of therapeutic alliance.  Future studies 
should include measures of therapeutic alliance so that synthesis of data (i.e., meta-analyses) 
can properly assess the effects of the therapeutic alliance on the outcome of therapy.   
Conclusion 
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 Psychotherapies for anxiety disorders are both highly efficacious (work in highly 
controlled settings) and highly effective (work in real-world settings). Exposure techniques 
enhance the effect of therapies, and are to be recommended for wide use with anxiety 
disorders.  Future research work is required to determine what else moderates the effect of 
such therapies.  
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Table 1. Overview of efficacy studies included in the main analyses. 
Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
2014 studies 
Asnaani et al. 
(2014) 
SAD AAT No LSAS 22 - - Not clearly 
reported 
Not clearly 
reported 
3-sessions 
Baker et al. 
(2014) 
PTSD WET Yes CAPS 19 19 12-
weeks 
Not clearly 
reported 
Not clearly 
reported 
5-sessions 
Chen et al. 
(2014) 
PTSD CBT No CRIES-13 10 10 3-Month Not clearly 
reported 
Not clearly 
reported 
6-Sessions 
Ehlers et al. 
(2014) 
PTSD Intensive CT Yes CAPS 30 30 40-Week 60% 39.7 (12.4) 7-days 
Ehlers et al. 
(2014) 
PTSD Weekly CT Yes CAPS 31 31 40-Week 58.10% 41.5 (11.7) 12-Sessions 
Ehlers et al. 
(2014) 
PTSD Weekly ST No CAPS 30 30 40-Week 56.70% 37.8 (9.9) 12-Sessions 
Kucketz et al. 
(2014) 
SAD AMP No LSAS 40 40 4-Month 65% 35.1 (13.3) 8-Sessions 
Kucketz et al. 
(2014) 
SAD AMP + FACT Yes LSAS 39 39 4-Month 69.20% 42 (13.3) 8-Sessions 
Kucketz et al. 
(2014) 
SAD iCBT Yes LSAS 40 40 4-Month 62.50% 39.5 (12) 9-Sessions 
Lloyd, et al. 
(2014) 
PTSD CPT Yes CAPS 30 30 3-Month Not reported Not 
reported 
12-sessions 
Newman et 
al. (2014) 
GAD CAGT No HARS 11 11 12-
Month 
54.50% 42.45 
(10.95) 
6-Sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Newman et 
al. (2014) 
GAD CBGT6 No HARS 14 13 12-
Month 
50% 45.19 
(12.61) 
6-Sessions 
Newman et 
al. (2014) 
GAD Group CBT No HARS 9 5 12-
Month 
77.80% 37.11 
(12.57) 
12-Sessions 
2013 studies           
Bonsaksen et 
al. (2013) 
SAD RCT 
(residential) 
No SPAI-SP 40 32 1-Year Not reported 37.7 (11.3) 40 group 
sessions & 
10 
individual  
Bonsaksen et 
al. (2013) 
SAD RIPT 
(residential) 
No SPAI-SP 40 37 1-Year Not reported 37.2 (11.6) 40 group 
sessions & 
10 
individual 
Farrell et al. 
(2013) 
OCD ERP + d-
cycloserine (25 
or 50 mg) 
Yes CYBOCS 9 9 3-Month Not clearly 
reported 
Not clearly 
reported 
9-sessions 
Farrell et al. 
(2013) 
OCD ERP + placebo 
(25 or 50 mg) 
Yes CYBOCS 8 8 3-Month Not clearly 
reported 
Not clearly 
reported 
9-sessions 
Foa et al. 
(2013) 
OCD SRI + ERP Yes YBOCS 38 - - 26% 36.1 (14.1) 8-Sessions 
Foa et al. 
(2013) 
OCD SRI + SRT Yes YBOCS 11 - - 45% 41.7 (11.7) 8-Sessions 
Hayes-
Skelton 
(2013) 
GAD ABBT No PSWQ 30 25 6-Month 60% 33.30 
(12.42) 
16-Sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Hoffart, et al. 
(2013) 
PTSD CBT - Imaginal 
Exposure 
Yes PTSD 
Symptom 
Scale-
Interview 
31 - - Not clearly 
reported 
Not clearly 
reported 
10-seasions 
Hoffart, et al. 
(2013) 
PTSD CBT Imagery 
Rescripting 
No PTSD 
Symptom 
Scale-
Interview 
34 - - Not clearly 
reported 
Not clearly 
reported 
10-seasions 
Hovland 
(2013) 
PD CBT Yes Panic-related 
distress/disab
ility 
19 19 6-Month 73.70% 37.8 (8.9) 12-Sessions 
Hovland 
(2013) 
PD Group physical 
exercise 
No Panic-related 
distress/disab
ility 
17 17 6-Month 88.20% 38.1 (8.6) 36-Sessions 
Kocovski et 
al. (2013) 
SAD CBGT Yes LSAS (CA) 
SPIN (ITT) 
32 (CA) 27 (CA) 3-Month 52.83% 32.66 (9.07) 12-Sessions 
12-Sessions 
53 (ITT) N/A (ITT) 
Kocovski et 
al. (2013) 
SAD MAGT No LSAS (CA) 
SPIN (ITT) 
37 (CA) 32 (CA) 3-Month 49.06% 34.94 
(12.52) 
12-Sessions 
12-Sessions 
53 (ITT) N/A (ITT) 
Ma et al. 
(2013) 
OCD  CCT + 
pharmacotherap
y 
No YBOCS 71 Not 
Reported 
Not 
included 
in 
analysis 
47.90% 27.4 (8.2 9-Sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Månsson et 
al. (2013) 
SAD iCBT Yes LSAS-LR 12 - - 85% 32.46 (8.6) 5-sessions 
Månsson et 
al. (2013) 
SAD Attention Bias 
Modification 
(internet) 
No LSAS-LR 12 - - 85% 32.08 (10.9) 10-sessions 
Margolies, et 
al. (2013) 
PTSD CBT for 
insomnia 
No PSS-SR 20 - - 10% 36.43 (9.3) 10-sessions 
Meyerbroeker 
et al. (2013) 
Agoraphobia 
with Panic 
Disorder 
CBT + VRET Yes PDSS 23 - - Not reported Not 
reported 
20-Sessions 
Meyerbroeker 
et al. (2013) 
Agoraphobia 
with Panic 
Disorder 
CBT + in vivo 
exposure 
Yes PDSS 21 - - Not reported Not 
reported 
20-Sessions 
Olatunji 
(2013) 
OCD CT Yes YBOCS 30 25 52-Week 83.33% 36.83 (9.80) 14-Sessions 
Olatunji 
(2013) 
OCD ERP Yes YBOCS 30 23 52-Week 65.63% 34.84 
(11.38) 
14-Sessions 
Reynolds et 
al. (2013) 
OCD CBT Yes CYBOCS 25 25 6-Month Not reported 14.4 (1.35) 6-sessions 
Reynolds et 
al. (2013) 
OCD Parent-enhanced 
CBT 
Yes CYBOCS 25 25 6-Month Not reported 14.6 (1.61) 6-sessions 
Rus-Calafell 
et al. (2013) 
Simple 
Phobia 
(Flying) 
VRET Yes Fear of 
Flying Scale 
7 7 6-Month 87.00% 37.14 
(14.28) 
17.43 (4.3) 
Sessions 
  
TREATMENT OF ANXIETY DISORDERS  51 
 
Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Rus-Calafell 
et al. (2013) 
Simple 
Phobia 
(Flying) 
Imaginal 
Exposure 
Yes Fear of 
Flying Scale 
8 8 6-Month Not reported 36.13 
(12.59) 
14.43 (5.3) 
Sessions 
Russell et al. 
(2013) 
OCD and 
ASD 
ERP yes YBOCS 20 18 1-Month 17.40% 28.6 (11.3) 12-Sessions 
Russell et al. 
(2013) 
OCD and 
ASD 
AM No YBOCS 20 17 1-Month 30.40% 25.2 (13.5) 12-Sessions 
Sannible et 
al. (2013) 
PTSD and 
AUD 
Integrated CBT 
for PTSD + 
AUD 
Yes CAPS 
severity 
33 33 9-Month 58% 41.85 
(12.62) 
17-Sessions 
Sannible et 
al. (2013) 
PTSD and 
AUD 
CBT for AUD + 
supportive 
counselling 
No CAPS 
severity 
29 29 9-Month 48% 40.41 
(11.21) 
10-weeks 
Simpson et 
al. (2013) 
OCD SSRI + ERP Yes YBOCS 37 - - 52.50% 34.3 (12.7) 10-weeks 
Sportel et al. 
(2013) 
SAD Group CBT Yes RCADS 84 84 12-
Month 
67% 14.06 (0.73) 14-sessions 
Sportel et al. 
(2013) 
SAD CBM No RCADS 86 86 12-
Month 
77% 14.12 (0.66) 14-sessions 
Storch et al. 
(2013) 
OCD Sertraline 
(standard dose) 
+ ERP 
Yes CYBOCS 14 - - 50% 11.57 (3.06) 14-sessions 
Storch et al. 
(2013) 
OCD Sertraline 
(titrated slowly) 
+ ERP 
Yes CYBOCS 17 - - 35.30% 11.47 (3.68) 2 sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Tart et al. 
(2013) 
Simple 
Phobia 
(Acrophobia) 
VRET + D-
Cycloserine 
Yes Acrophobia 
avoidance 
questionnaire 
15 15 1-Month Not reported 29.33 
(14.67) 
4-sessions 
Tart et al. 
(2013) 
Simple 
Phobia 
(Acrophobia) 
VRET + Pill 
Placebo 
Yes Acrophobia 
avoidance 
questionnaire 
14 14 1-Month Not reported 37.71 
(16.81) 
4-sessions 
Zang et al. 
(2013) 
PTSD NET Yes HADS - 
anxiety 
11 11 2-Month 73% 56.64 
(12.22) 
2 to 3 
sessions 
Zang et al. 
(2013) 
PTSD NET (post-wait 
list) 
Yes HADS - 
anxiety 
11 11 2-Month 82% 54.82 
(11.59) 
2 to 3 
sessions 
2012 studies           
Aldahandha 
et al. (2012) 
PTSD EMDR Yes Trauma 
Systems 
Inventory 
25 22 1-Month 52% Not clearly 
reported 
10-Sessions 
Aldahandha 
et al. (2012) 
PTSD EMDR (after 
Wait List) 
Yes Trauma 
Systems 
Inventory 
26 22 1-Month 53.85% Not clearly 
reported 
10-Sessions 
Andersson 
(2012) 
OCD iCBT Yes YBOCS 49 50 4-Month 66% 33 (12) 12-sessions 
Andersson 
(2012) 
OCD Attention 
Control 
No YBOCS 51 - 4-Month 66.70% 35 (14) 12-sessions 
de Oliveira et 
al. (2012) 
SAD TBTR No LSAS 17 17 12-
Month 
70.60% 33.9 (9.9) 12-sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
de Oliveira et 
al. (2012) 
SAD CT No LSAS 19 19 12-
Month 
78.90% 34.9 (13.4) 8-sessions 
and one 
one-day 
meditation 
retreat 
Jazaieri et al. 
(2012) 
SAD MBSR No LSAS 24 16 3-Month 61.30% 32.87 (8.83) 5-sessions 
Nations et al. 
(2012) 
PD CBT + Org 
25935 (4 mg) 
Yes PDSS 10 10 1-Month 63.60% 33.3 (11.0) 5-sessions 
Nations et al. 
(2012) 
PD CBT + Org 
25935 (12 mg) 
Yes PDSS 14 14 1-Month 60% 36.4 (8.9) 1-session 
Nations et al. 
(2012) 
PD CBT + Placebo Yes PDSS 13 13 1-Month 78.60% 32.4 (11.2) 1-session 
Nave et al. 
(2012) 
Simple 
Phobia 
(arachnophob
ia) 
Exposure + D-
Cyloserine 
Yes CGI-S 10 - - 60% 34.6 (12.69) 9-Sessions 
Nave et al. 
(2012) 
Simple 
Phobia 
(arachnophob
ia) 
Exposure + 
Placebo 
Yes CGI-S 10 - - 60% 39 (13.91) 9-Sessions 
Nixon et al. 
(2012) 
PTSD CBT Yes CAPS 17 17 6-Month 47% 11.59 (3.31) 8-Sessions 
Nixon et al. 
(2012) 
PTSD CT No CAPS 17 17 6-Month 25% 10 (2.48) 24.6 (4.2) 
Sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Willutzki et 
al. (2012) 
SAD CT No social phobia 
scale 
23 16 2-Year 43.80% Not clearly 
reported 
12-sessions 
Willutzki et 
al. (2012) 
SAD ROCBT No social phobia 
scale 
40 35 2-Year 40% Not clearly 
reported 
6-lessons 
2011 studies           
Alden et al. 
(2011) 
SAD interpersonal 
CBT 
No SIAS 27 21 6-Month 35% 34.7 (SD 
not 
reported) 
7-Sessions 
Andrews et 
al. (2011) 
SAD iCBT Yes SIAS 21 - - Not clearly 
reported 
Not clearly 
reported 
18-sessions 
Andrews et 
al. (2011) 
SAD Group CBT No (can’t 
tell) 
SIAS 14 - - Not clearly 
reported 
Not clearly 
reported 
29-sessions 
Belloch et al. 
(2011) 
OCD CT No PSWQ 16 16 - 62.50% 30.44 (5.70) 14-sessions 
Bidel et al. 
(2011) 
PTSD Trauma 
Management 
Therapy  
Yes CAPS 14 - - 0% 58.93 (SD 
not 
reported) 
12-sessions 
Bidel et al. 
(2011) 
PTSD Exposure 
Therapy  
Yes CAPS 16 - - 0% 59.76 (SD 
not 
reported) 
5-sessions 
Bolton (2011) OCD CBT No CYBOCS 36 36 3-Month 58% 15 (2.5) 15-sessions 
Bolton (2011) OCD Brief CBT No CYBOCS 36 36 3-Month 64% 14.33 (2.33) 15-sessions 
Hedman et al. 
(2011) 
SAD iCBT Yes LSAS 64 64 6-Month 37.50% 35.1 (11.1) 10-Sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Hensel-
Dittman 
(2011) 
PTSD NET Yes CAPS 11 7 1-Year Not reported Not 
reported 
14-sessions 
Hensel-
Dittman 
(2011) 
PTSD SIT No CAPS 10 8 1-Year Not reported Not 
reported 
14-sessions 
Hinton et al. 
(2011) 
PTSD 
(treatment 
resistant) 
CBT (culturally 
adapted) 
No PCL 12 12 12-Week 100% 47.6 (8.2) 16-sessions 
+ 3 boosters 
Hinton et al. 
(2011) 
PTSD 
(treatment 
resistant) 
Applied Muscle 
Relaxation 
No PCL 12 12 12-Week 100% 51.4 (5.9) 16-sessions 
+ 3 boosters 
Jónsson et al. 
(2011) 
OCD Group CBT Yes YBOCS 42 31 1-Year 59.60% 32.7 (11.1) 8-sessions 
Jónsson et al. 
(2011) 
OCD CBT Yes YBOCS 37 26 1-Year 71.70% 32.7 (9.5) 8-sessions 
Karatzias et 
al. (2011) 
PTSD EMDR Yes CAPS 23 23 3-Month 60.90% 41.5 (10.8) 24-sessions 
Karatzias et 
al. (2011) 
PTSD Emotional 
freedom 
techniques 
Yes CAPS 23 23 3-Month 52.20% 39.7 (10.9) 16-Sessions 
Melfsen et al. 
(2011) 
SAD CBT No ADIS for 
Children 
German 
version 
15 - - 38.10% 10.60 (1.64) 16-Sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Mörtberg et 
al. (2011) 
SAD CT No LSAS 23 23 5-Year 69% 36.1 (9.8) 14-sessions 
Nacasch 
(2011) 
PTSD PE Yes PSS-I 15 15 at least 
12-
months 
after 
treatment 
Not reported 34.8 (11.4) 8-Sessions 
Newman et 
al. (2011) 
GAD CBT + 
Supportive 
Listening 
No PSWQ 40 40 24-
Month 
80% 37.39 
(11.99) 
8-sessions 
Paxling et al. 
(2011) 
GAD iCBT Yes PSWQ 44 44 3-Year 82.82% 40 (11.3) 8-sessions 
Price & 
Anderson 
(2011) 
SAD Group CBT Yes Fear of 
Negative 
Evaluation -
Brief Form 
51 - - Not clearly 
reported 
Not clearly 
reported 
8-sessions 
Price and 
Anderson 
(2011) 
SAD Group CBT + 
VRET 
Yes Fear of 
Negative 
Evaluation -
Brief Form 
40 - - Not clearly 
reported 
Not clearly 
reported 
1-session 
Price, Mehta, 
et al. (2011) 
SAD VRET Yes Personal 
Report of 
Confidence 
as a Speaker 
31 - - Not clearly 
reported 
Not 
reported 
1-session 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
           
Raes et al. 
(2011) 
Simple 
Phobia 
(arachnophob
ia) 
One-session 
exposure 
(Exposure only) 
Yes Spider 
Phobia 
Questionnair
e 
16 16 1-Month Not clearly 
reported 
Not clearly 
reported 
10-sessions 
Raes et al. 
(2011) 
Simple 
Phobia 
(arachnophob
ia) 
One-session 
exposure 
(Behavioural 
experiments) 
Yes Spider 
Phobia 
Questionnair
e 
15 15 1-Month Not clearly 
reported 
Not clearly 
reported 
10-sessions 
Rakowska 
(2011) 
SAD BST Yes SCL-PHOB 30 30 3-Month Not clearly 
reported 
Not clearly 
reported 
16-sessions 
Rakowska 
(2011) 
Sad and 
personality 
disorder 
BST Yes SCL-PHOB 30 30 3-Month Not clearly 
reported 
Not clearly 
reported 
16-sessions 
Stangier et al. 
(2011) 
SAD CT No LSAS 38 38 1-Year 44.70% 34.6 (12.9) 14-sessions 
Stangier et al. 
(2011) 
SAD interpersonal 
psychotherapy 
No LSAS 38 38 1-Year 57.90% 33.9 (9.5) 20-sessions 
Storch et al. 
(2011) 
OCD CBT (family 
based, 
teletherapy) 
yes CYBOCS 16 14 3-Month 37% 11.00 (2.5) 17-sessions 
Tolin et al. 
(2011) 
OCD Stepped-care 
ERP 
Yes YBOCS 19 19 - 68.40% 35.95 
(15.16) 
6-sessions 
Tolin et al. 
(2011) 
OCD ERP Yes YBOCS 15 15 - 46.70% 31.33 
(10.50) 
6-sessions 
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Study Disorder Treatment1 Exposure Measure2 N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
%  female 
participants 
Age M (SD) Treatment 
Length 
Tortella-Feliu 
et al. (2011) 
Simple 
Phobia 
(flying) 
Self-
administered 
computer-aided 
exposure 
Yes Fear of 
Flying Scale 
21 21 1-Year 47.62% 
based on 
reported n of 
10 females 
out of 21 
(authors 
reported: 
52.8%, this 
is accurate if 
n is 11) 
36.24 (8.51) 3-sessions 
Tortella-Feliu 
et al. (2011) 
Simple 
Phobia 
(flying) 
VRET Yes Fear of 
Flying Scale 
19 19 1-Year 52.63% 36.89 
(11.71) 
3-sessions 
1ABBT - Acceptance Based Behaviour Therapy; AM - Anxiety Management; AMP - Attention Modification Program; AMP + FACT - 
Attention Modification Program + Fear Activation; AAT - Approach-Avoidance Task; BST - Brief Strategic Therapy; CAGT - Computer-
Assisted Group CBT; CBM - Cognitive Bias Modification; CBGT6 - Six-session Group CBT; CBGT - Group CBT; CBT - Cognitive 
Behavioural Therapy; CCT - Cognitive-Coping Therapy; CPT - Cognitive Processing Therapy; CT - Cognitive Therapy; ERP - Exposure and 
Response/Ritual Prevention; iCBT - Internet-delivered/based CBT; MAGT - Mindfulness and Acceptance-Based Therapy; MBSR - 
Mindfulness-Based Stress Reduction; MCT - Metacognitive Therapy; NET - Narrative Exposure Therapy; RCT - Residential Cognitive Group 
Therapy; RIPT - Residential Interpersonal Group Therapy; ROCBT - Resource-Orientated Cognitive Behavioural Therapy; SIT - Stress 
Incoulation Training; SRI - Seretonin Reuptake Inhibitor; SSRI - Selective Seretonin Reuptake Inhibitor; SRT - Stress Managment Training; ST 
- Supportive Therapy; TBTR - Trial-based Cognitive Therapy; WET - Written Exposure Therapy; VRET - Virtual reality exposure therapy. 
2ADIS - Anxiety Disorders Interview Schedule; CAPS - Clinician administered PTSD scale;  CGI-S: Clinical Global Impression - Severity 
Scale; CRIES-13 - Children's Revised Impact of Event Scale; CYBOCS- Children's Yale-Brown Obsessive-Compulsive Scale; HADS - Hospital 
Anxiety and Depression Scale; HARS - Hamilton Anxiety Rating Scale; LSAS - Liebowitz Social Anxiety Scale; LSAS-SR - Liebowitz Social 
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Anxiety Scale - Self-report; PCL - PTSD Checklist; PDS - Post Traumatic Stress Diagnostic Scale; PDSS - Panic Disorder Severity Scale; PSS-I 
- PTSD Symptom Scale-Interview; PSS-SR - PTSD Symptom Scale-Self-Report; PSWQ - Penn State Worry Questionnaire; RCADS - Revised 
Children's Anxiety and Depression Scale; SCL-PHOB - Derogatis Symptom Checklist - Phobic Anxiety; SIAS - Social Interaction Anxiety 
Scale; SPIN - Social Phobia Inventory; YBOCS - Yale-Brown Obsessive-Compulsive Scale. 
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Table 2. Overview of effectiveness studies included in the main analyses. 
Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
2014 studies 
Dalrymple et 
al. (2014) 
SAD and a 
depressive 
disorder 
ACT Yes LSAS (Fear 
subscale) 
18 (CA) - - 45.90% 36.43 
(13.0) 
16-Sessions 
38 (ITT) 
Jeffreys et al. 
(2014) 
PTSD CPT-G Yes PCL 20 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Jeffreys et al. 
(2014) 
PTSD CPT Yes PCL 7 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Jeffreys et al. 
(2014) 
PTSD CPT-C Yes PCL 150 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Jeffreys et al. 
(2014) 
PTSD PE Yes PCL 81 - - 5.90% 38.2 
(13.26) 
10 to 15-
Sessions 
Matulis et al. 
(2014) 
PTSD CPT 
(developmental
ly adapted) 
Yes CAPS 12 12 6-Week Not reported 18.08 
(1.67) 
30-Sessions 
Shirotsuki et 
al. (2014) 
SAD CBT Yes SFNE 15 - - 46.67% 30.06 
(No SD 
reported) 
6-Sessions 
Wesner et al. 
(2014) 
PD Group CBT Yes CGI 48 - - 75% 38.8 
(11.1) 
12-Sessions 
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Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
2013 studies           
da la Cruz et 
al. (2013) 
OCD ERP Yes CYBOCS 50 - - Not clearly 
reported 
Not 
clearly 
reported 
13-Sessions 
da la Cruz et 
al. (2013) 
OCD ERP Yes CYBOCS 103 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Dèttore, et al. 
(2013) 
OCD ERP Yes YBOCS 38 - - 50% 33.38 
(9.44) 
50 Sessions 
Eftekhari et 
al. (2013) 
PTSD PE Yes PCL 1389 (CA) - - 12.90% 46.8 
(14.3) 
9 (4.2) 
Seasons 1888 
(ITT) 
Furukawa et 
al. (2013) 
SAD CBGT Yes LSAS 52 Not 
included 
Follow-
up 
reported 
using a 
different 
measure 
50% 35.5 
(9.3) 
13.4 (4.5) 
Seasons 
King, et al. 
(2013) 
PTSD MBCT No CAPS 15 (CA) - - Not reported 60.1 
(9.7) 
8-Sessions 
20 (ITT) 
Kleim, et al. 
(2013) 
PTSD TF-CBT No PDSS 268 - - 58.60% 38.67 
(11.26) 
12-Sessions 
Najavits et al. 
(2013) 
PTSD Seeking Safety No Basis-32 7 - - 57% 45.89 
(10.61) 
18.86 (8.17) 
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Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
Sripada et al. 
(2013) 
PTSD PE Yes PCL-S 51 CA - - Not reported 49.3 (No 
SD 
reported) 
12 (2.7) CA 
10 (3.8) ITT 40 ITT 
Stott et al. 
(2013) 
SAD Internet-
delivered CT 
Yes LSAS 11 - - 45% 33.1 
(5.9) 
13.7 (4.0) 
Weeks 
van der 
Helden et al. 
(2013) 
GAD Group 
Metacognitive 
Therapy 
Yes PSWQ 24 (CA) 14 (CA) 6-Month 63.64% 31.33 
(8.96) 
14-Sessions 
33 (ITT) 33 (ITT) 
Voder et al. 
(2013) 
PTSD PE Yes PCL-M 55 (CA) - - 0% 64.92 
(5.35) 
12.67 (6.94) 
(CA) 
11.37 (6.94) 
(ITT) 
66 (ITT) 
Yuen et al. 
(2013) 
SAD ABBT Yes LSAS 26 26 3-Month 25% 35 (10.8) 12-Sessions 
2012 studies           
Tarquinio et 
al. (2012) 
PTSD EMDR Yes IES Total 12 12 6-Month 100% 33 (4.6) 5-Session 
Wagner et al. 
(2012) 
PTSD iCBT No PDS 15 - - 86.70% 29.3 
(7.1) 
Not reported 
(10 
assignments) 
Wroe et al. 
(2012) 
OCD Group CBT Yes YBOCS 15 - - 54.50% 35 
(10.54) 
7 to 8 
sessions 
2011 studies           
Alvarez et al. 
(2011) 
PTSD CPT 
(residential) 
Yes PCL 104 - - 0% 50.20 
(11.55) 
14-Sessions 
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Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
Ayers et al. 
(2011) 
OCD 
(hoarding) 
CBT Yes UCLA 
Hoarding 
Severity 
Scale 
12 10 6-Month 58.33% 73.66 
(6.54) 
26 sessions 
Chard et al. 
(2011) 
PTSD and 
mild TBI 
CPT 
(residential) 
No CAPS 28 - - 0% 33.93 
(8.59) 
14.11 (1.17) 
sessions 
7-weeks (2 
group and 
minimum of 
2 individual a 
week) 
Chard et al. 
(2011) 
PTSD and 
moderate/seve
re TBI 
CPT 
(residential) 
No CAPS 14 - - 0% 38.7 
(10.59) 
14.71 (1.98) 
Sessions 
7-weeks (2 
group and 
minimum of 
2 individual a 
week) 
Gros, 
Antony, et al. 
(2011) 
PD Group CBT Yes ASI 32 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Gros, 
Antony, et al. 
(2011) 
PD and 
Irritable 
Bowel 
Syndrome 
Group CBT Yes ASI 23 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
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Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
Gros, Yoder, 
et al. (2011) 
PTSD PE Yes PCL-M 27 - - 11.10% 45.2 
(16.0) 
12-Sessions 
Haraguchi et 
al. (2011) 
OCD Group CBT Yes YBOCS 28 (CA) - - 82.1% (CA) 
77.8% (ITT) 
32.6 
(10.7) 
(CA) 
30.9 
(10.3) 
(ITT) 
12-Sessions 
36 (ITT) 
Hindo et al. 
(2011) 
SAD One-Session 
Exposure 
Yes LSAS 32 23 1-Month 75% 28.25 
(9.22) 
1-Session 
Long et al. 
(2011) 
PTSD Imagery 
Rescripting and 
Exposure 
Therapy 
Yes PCL-M 33 - - 0% 62.1 6-Sessions 
Nakatani et 
al. (2011) 
OCD CBT/ERP Yes CYBOCS 40 - - 41.10% 12.5 
(2.9) 
12-Sessions 
Nakatani et 
al. (2011) 
OCD CBT/ERP Yes CYBOCS 69 - - 41.60% 14.7 
(1.7) 
12-Sessions 
Nevo et al. 
(2011) 
PTSD PE (TMT) Yes CPSS 
patient 
15 15 1-Month 86% 10.8 
(4.39) 
7 to 16-
Sessions 
Nixon et al. 
(2011) 
PTSD and 
MDD 
Behavioural 
activation, 
Cognitive 
Restructuring, 
and exposure 
Yes CAPS 20 20 3-Month 85% 45.3 
(11.88) 
12 to 16 
sessions 
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Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
Telch et al. 
(2011) 
PD CBT Yes SPRAS 119 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Telch et al. 
(2011) 
PD and 
personality 
disorder 
CBT Yes SPRAS 54 - - Not clearly 
reported 
Not 
clearly 
reported 
12-Sessions 
Turek et al. 
(2011) 
PTSD PE Yes PCL-M 43 (CA) - - 11% 31.77 
(8.19) 
7 (5) sessions 
(ITT) 
10 (4) 
sessions (CA) 
65 (ITT) 
Westra et al. 
(2011) 
GAD CBT Yes PSWQ 11 11 1-Year 63.64% 41.36 
(SD not 
reported) 
6-Sessions 
Westra et al. 
(2011) 
GAD CBT Yes PSWQ 6 6 1-Year 83.33% 49.83 
(SD not 
reported) 
6-Sessions 
Westra et al. 
(2011) 
GAD CBT Yes PSWQ 8 8 1-Year 87.50% 33.75(SD 
not 
reported) 
6-Sessions 
Westra et al. 
(2011) 
GAD CBT Yes PSWQ 7 7 1-Year 57.14% 42.86 
(SD not 
reported) 
6-Sessions 
Wetherall et 
al. (2011) 
GAD CBT + 
Escitalopram 
No HAMA 10 - - 60% 68.6 
(8.59) 
16-Sessions 
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Study Disorder Treatment1 Exposure2 Measure N used in 
pre-/post- 
analysis 
N used in 
follow-up 
analysis 
Follow-
up 
length 
% female 
participants 
Age M 
(SD) 
Treatment 
Length 
Wootton et 
al. (2011) 
OCD iCBT Yes YBOCS 21 21 3-Month 59% 35.18 
(11.32) 
8-lessons 
 
1ABBT - Acceptance Based Behaviour Therapy; ACT - Acceptance and Commitment Therapy; CBGT - Group CBT; CBT - Cognitive 
Behavioural Therapy; CPT -  Cognitive Processing Therapy; CPT-G - Cognitive Processing Therapy - Group; CT - Cognitive Therapy; EMDR - 
Eye Movement Desensitization and Reprocessing; ERP - Exposure and Response/Ritual Prevention; ICBT - Internet-delivered/based CBT; 
MBCT - Mindfulness-based Cognitive Therapies; PE - Prolonged Exposure; PE (TMT) - Prolonged Exposure (Trauam Mastery Therapy); TF-
CBT - Trauma-Focused Cognitive Behavioural Therapy. 
2ASI - Anxiety Sensitivity Index; Basis-32 - Behavior And Symptom Identification Scale; CAPS - Clinician Administered PTSD Scale; CGI - 
Clinical Global Impression; CPSS - Child PTSD symptom Scale; CYBOCS - Children's Yale-Brown Obsessive-Compulsive Scale; HAMA - 
Hamilton Anxiety Rating Scale; IES - Impact of Event Scale; LSAS - Liebowitz Social Anxiety Scale; PCL - PTSD Checklist; PCL-C - PTSD 
Checklist - Civilian; PCL-M - PTSD Checklist - Military; PCL-S - PTSD Checklist - Specific; PDS - Post Traumatic Stress Diagnostic Scale; 
PDSS - Panic Disorder Severity Scale; PSWQ - Penn State Worry Questionnaire; SPARS - Sheehan Patient-Related Anxiety Scale; SFNE - 
Short Fear of Negative Evaluation Scale; YBOCS - Yale-Brown Obsessive-Compulsive Scale. 
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Table 3. Methodological quality (CASP RCT rating) of efficacy studies included in the main analyses.  
Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
2014 studies             
Asnaani et al. (2014) Y Y Y Y Y Y Small 51.18 - 67.82 N N Y 7 
Baker et al. (2014) Y Y Y CT CT Y Large 13.67 - 24.23 CT CT Y 5 
Chen et al. (2014) Y Y CT CT N N Large 22.59 - 31.81 Y CT Y 4 
Ehlers et al. (2014) Y Y Y N Y Y Large 22.49 - 41.95 Y Y Y 8 
Ehlers et al. (2014) Y Y Y N Y Y Large 16.87 - 37.07 Y Y Y 8 
Ehlers et al. (2014) Y Y Y N Y Y Large 36.51 - 59.25 Y Y Y 8 
Kucketz et al. (2014) Y Y Y CT CT Y small 58.86 - 76.24 Y Y Y 7 
Kucketz et al. (2014) Y Y Y CT CT Y Large 42.45 - 56.21 Y Y Y 7 
Kucketz et al. (2014) Y Y Y CT CT Y Large 37.57 - 49.89 Y Y Y 7 
Lloyd, et al. (2014) Y Y CT CT Y N Large 38.05 - 58.01 Y N Y 5 
Newman et al. (2014) Y Y CT Y Y Y Large 7.4 - 13.36 Y Y Y 8 
Newman et al. (2014) Y Y CT Y Y Y Large 9.25 - 15.83 Y Y Y 8 
Newman et al. (2014) Y Y CT Y Y Y Large 9.55 - 21.45 Y Y Y 8 
2013 studies             
Bonsaksen et al. (2013) Y Y CT Y Y Y Large 97.99 - 119.83 Y Y Y 8 
Bonsaksen et al. (2013) Y Y CT Y Y Y Large 103.66 - 124.24 Y Y Y 8 
Farrell et al. (2013) Y Y CT Y CT Y Large 10.32 - 17.24 CT Y Y 6 
Farrell et al. (2013) Y Y CT Y CT Y Large 8.41 - 19.09 CT Y Y 6 
Foa et al. (2013) Y Y Y Y Y Y Large 10.13 - 12.87 Y N Y 8 
Foa et al. (2013) Y Y Y Y Y Y Large 14.22 - 19.78 Y N Y 8 
Hayes-Skelton (2013) Y CT CT N Y Y Large 48 - 54.06 Y N Y 5 
Hayes-Skelton (2013) Y CT CT N Y Y Large 48.63 - 55.93 Y N Y 5 
Hoffart, et al. (2013) Y Y Y CT Y Y Large 15.06 - 24.74 Y N Y 7 
Hoffart, et al. (2013) Y Y Y CT Y Y Large 17.91 - 27.51 Y N Y 7 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Hovland (2013) Y Y Y CT Y Y Large 0.17 - 1.35 Y Y Y 8 
Kocovski et al. (2013) Y Y Y Y Y Y Medium 29.94 - 37.5 (ITT) Y Y Y 9 
Kocovski et al. (2013) Y Y Y Y Y Y Large 29.93 - 37.89 (ITT) Y Y Y 9 
Ma et al. (2013) Y Y Y N Y CT Large 13.52 - 16.08 Y N Y 6 
Månsson et al. (2013) Y Y Y Y Y Y Large 32.49 - 67.01 Y N Y 8 
Månsson et al. (2013) Y Y Y Y Y Y Large 46.72 - 64.94 Y N Y 8 
Margolies, et al. (2013) Y Y CT Y Y Y Medium 27.5 – 39.5 Y N N 6 
Meyerbroeker et al. (2013) Y Y N Y Y Y Large 0.66 - 1.4 Y N Y 7 
Meyerbroeker et al. (2013) Y Y N Y Y Y Large 0.64 - 1.38 Y N Y 7 
Olatunji (2013) Y Y Y Y Y Y Large 12.92 - 19.34 Y Y Y 9 
Olatunji (2013) Y Y Y Y Y Y Large 12.97 - 19.29 Y Y Y 9 
ReyNlds et al. (2013) Y Y Y Y Y Y Large 10.96 - 17.68 Y Y Y 9 
ReyNlds et al. (2013) Y Y Y Y Y Y Large 10.74 - 17.42 Y Y Y 9 
Rus-Calafell et al. (2013) Y Y CT Y Y Y Large 38.53 - 60.05 Y Y Y 8 
Rus-Calafell et al. (2013) Y Y CT Y Y Y Large 38.94 - 60.32 Y Y Y 8 
Russell et al. (2013) Y Y Y Y Y Y Large 14.12 - 21.48 Y Y Y 9 
Russell et al. (2013) Y Y Y Y Y Y Medium 17.43 - 24.17 Y Y Y 9 
Sannible et al. (2013) Y Y Y Y Y Y Large 33.78 - 51.82 Y Y Y 9 
Sannible et al. (2013) Y Y Y Y Y Y Large 37.15 - 56.27 Y Y Y 9 
Simpson et al. (2013) Y Y Y Y Y Y Large 11.03 - 14.97 Y N Y 8 
Sportel et al. (2013) Y Y Y Y Y Y small 11.31 - 13.39 Y Y Y 9 
Sportel et al. (2013) Y Y Y Y Y Y Medium 10.19 - 12.49 Y Y Y 9 
Storch et al. (2013) Y Y Y Y Y Y Large 10.34 - 20.52 Y N Y 8 
Storch et al. (2013) Y Y Y Y Y Y Large 13.57 - 20.79 Y N Y 8 
Storch et al. (2013) Y Y Y Y Y Y Large 12.32 - 18.8 Y N Y 8 
Tart et al. (2013) Y Y Y CT Y Y Large 5.25 - 12.75 Y Y Y 8 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Zang et al. (2013) Y Y Y Y Y Y Large 3.6 - 6.94 CT N Y 7 
Zang et al. (2013) Y Y Y Y Y Y Large 3.13 - 6.87 CT N Y 7 
2012 studies             
Aldahandha et al. (2012) Y Y CT CT Y Y Lage 41.76 - 45.76 CT N Y 5 
Aldahandha et al. (2012) Y Y CT CT Y Y Lage 42.68 - 47.7 CT N Y 5 
Andersson (2012) Y Y Y Y Y Y Large 11.19 - 14.69 Y Y Y 9 
Andersson (2012) Y Y Y Y Y Y Medium 17.73 - 20.03 Y N Y 8 
de Oliveira et al. (2012) Y Y CT Y Y Y Large 39.95 - 71.35 Y Y Y 8 
de Oliveira et al. (2012) Y Y CT Y Y Y Large 50.07 - 73.29 Y Y Y 8 
Jazaieri et al. (2012) Y Y CT CT Y Y Large 48.09 - 62.91 Y N Y 6 
Nations et al. (2012) Y Y Y N Y Y Large 4.38 - 6.22 Y Y CT 7 
Nations et al. (2012) Y Y Y N Y Y Large 5.18 - 10.02 Y Y CT 7 
Nations et al. (2012) Y Y Y N Y Y Large 4.27 - 8.93 Y Y CT 7 
Nave et al. (2012) Y Y Y Y Y Y Large 2.29 - 3.71 Y N Y 8 
Nave et al. (2012) Y Y Y Y Y Y Large 2.28 - 3.12 Y N Y 8 
Nixon et al. (2012) Y Y Y Y Y Y Large 12.97 - 37.27 Y Y Y 9 
Nixon et al. (2012) Y Y Y Y Y Y Large 13.82 - 37.68 Y Y Y 9 
Wells et al. (2012) Y Y N Y CT Y Large 6.64 - 26.96 Y N Y 6 
Willutzki et al. (2012) Y Y CT CT CT Y Large 14.39 - 23.53 Y CT CT 4 
Willutzki et al. (2012) Y Y CT CT CT Y Large 13.94 - 22.42 Y CT CT 4 
2011 studies             
Alden et al. (2011) Y Y CT Y Y Y Large 30.34 - 39.52 Y Y Y 8 
Andrews et al. (2011) Y Y N CT Y Y Medium 37.2 - 50.8 Y N Y 6 
Andrews et al. (2011) Y Y N CT Y Y Large 34.06 - 53.66 Y N Y 6 
Belloch et al. (2011) Y Y N N N Y Medium 44.32 - 57.14 Y Y Y 6 
Bidel et al. (2011) Y Y CT Y Y Y Large 56.43 - 81.57 Y N Y 7 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Bolton (2011) Y Y Y Y Y Y Large 6.89 - 12.11 Y Y Y 9 
Bolton (2011) Y Y Y Y Y Y Large 9.86 - 16.14 Y Y Y 9 
Hedman et al. (2011) Y Y Y Y Y Y Large 34.52 - 44.28 Y Y Y 9 
Hedman et al. (2011) Y Y Y Y Y Y Large 42.28 - 54.72 Y Y Y 9 
Hensel-Dittman (2011) Y Y N Y Y Y Large 61.25 - 92.21 Y N Y 7 
Hensel-Dittman (2011) Y Y N Y Y Y Small 70.95 - 94.25 Y N Y 7 
Hinton et al. (2011) Y Y CT Y Y Y Large 30.56 - 47.64 Y N Y 7 
Hinton et al. (2011) Y Y CT Y Y Y Large 54.13 - 69.07 Y N Y 7 
Jónsson et al. (2011) Y Y N Y Y Y Large 16.35 - 21.31 Y Y Y 8 
Jónsson et al. (2011) Y Y N Y Y Y Large 15.69 - 21.01 Y Y Y 8 
Karatzias et al. (2011) Y Y Y Y Y Y Large 30.4 - 55 Y Y Y 9 
Karatzias et al. (2011) Y Y Y Y Y Y Large 29.75 - 51.25 Y Y Y 9 
Melfsen et al. (2011) Y Y CT Y Y Y Large 2.86 - 4 Y N Y 7 
Mörtberg et al. (2011) Y Y Y Y Y Y Large 45.34 - 59.46 Y Y Y 9 
Mörtberg et al. (2011) Y Y Y Y Y Y Large 36.98 - 57.42 Y Y Y 9 
Nacasch (2011) Y Y Y N Y Y Large 14.29 - 23.51 Y Y Y 8 
Newman et al. (2011) Y Y CT N N Y Large 45.61 - 52.51 N N N 3 
Paxling et al. (2011) Y Y Y Y Y Y Large 53.98 - 61.66 Y Y Y 9 
Price and Anderson (2011) Y Y CT Y Y Y Large 33.3 - 36.96 Y N Y 7 
Price and Anderson (2011) Y Y CT Y Y Y Small 34.89 - 40.67 Y N Y 7 
Price, Mehta, et al. (2011) Y Y CT CT CT N Large 13.86 - 18.98 Y N Y 4 
Raes et al. (2011) Y Y Y Y Y N Large 10.04 - 13.46 Y Y Y 8 
Raes et al. (2011) Y Y Y Y Y N Large 8.27 - 13.73 Y Y Y 8 
Rakowska (2011) Y Y CT Y Y Y Large 0.09 - 0.51 Y Y Y 8 
Rakowska (2011) Y Y CT Y Y Y Large 0.54 - 0.98 Y Y Y 8 
Stangier et al. (2011) Y Y Y Y Y Y Large 32.78 - 46.2 Y Y Y 9 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Storch et al. (2011) Y Y Y CT Y Y Large 5.97 - 16.29 Y N Y 7 
Tolin et al. (2011) Y Y Y Y Y Y Large 12.67 - 17.65 Y Y Y 9 
Tolin et al. (2011) Y Y Y Y Y Y Large 11.12 - 17.38 Y Y Y 9 
Tortella-Feliu et al. (2011) Y Y CT Y Y Y Large 44.25 - 54.95 Y N Y 7 
Tortella-Feliu et al. (2011) Y Y CT Y Y Y Large 41.07 - 50.33 Y N Y 7 
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Table 4. Methodological quality (CASP cohort rating) of effectiveness studies included in the main analyses. 
Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
2014 studies             
Dalrymple et al. (2014) Y Y Y N (a) N 
(b) N 
(a) N 
(b) N 
Large 34.81 - 45.05 (ITT) CT CT CT 3 
Jeffreys et al. (2014) Y CT CT CT (a) CT 
(b) CT 
(a) N 
(b) N 
Large 47.44 - 57.46 Y Y Y 4 
Jeffreys et al. (2014) Y CT CT CT (a) CT 
(b) CT 
(a) N 
(b) N 
Large 25.86 - 39 Y Y Y 4 
Jeffreys et al. (2014) Y CT CT CT (a) CT 
(b) CT 
(a) N 
(b) N 
Large 51.95 - 56.27 Y Y Y 4 
Jeffreys et al. (2014) Y CT CT CT (a) CT 
(b) CT 
(a) N 
(b) N 
Large 30.33 - 35.19 Y Y Y 4 
Matulis et al. (2014) Y Y Y Y (a) N 
(b) N 
(a) Y 
(b) N 
Large 22.38 - 55.78 Y Y Y 8 
Shirotsuki et al. (2014) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 32.26 - 43.08 Y Y Y 9 
Wesner et al. (2014) Y Y Y Y (a) CT 
(b) CT 
(a) N  
(b) N 
Large 2.39 - 3.01 Y Y Y 7 
2013 studies             
da la Cruz et al. (2013) Y Y CT N (a) N 
(b) N 
(a) N 
(b) N 
Large 12.95 - 17.45 CT Y Y 4 
da la Cruz et al. (2013) Y Y CT N (a) N 
(b) N 
(a) N 
(b) N 
Large 12.54 - 15.66 CT Y Y 4 
Dèttore, et al. (2013) CT Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 15.83 - 20.85 Y Y Y 8 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Eftekhari et al. (2013) Y Y Y Y (a) N 
(b) Y 
(a) N 
(b) N 
Medium 47.04 - 48.96 (ITT) Y Y CT 7 
Furukawa et al. (2013) Y Y Y Y (a) N 
(b) Y 
(a) N 
(b) Y 
Large 46.79 - 60.21 Y Y Y 9 
King, et al. (2013) Y CT Y Y (a) N 
(b) N 
(a) N 
(b) N 
Medium 52.48 - 72.72 (ITT) CT CT CT 3 
Kleim, et al. (2013) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 0.98 - 1.16 Y N Y 8 
Najavits et al. (2013) Y Y Y Y (a) N  
(b) N 
(a) N  
(b) N 
Large 0.24 - 1.16 CT CT CT 2 
Plagge et al. (2013) Y Y Y Y (a) Y 
(b) N 
(a) N 
(b) N 
Medium 49.63 - 59.57 Y Y Y 8 
Sripada et al. (2013) Y Y Y Y (a) CT 
(b) CT 
(a) N 
(b) N 
Large 83.11 - 101.49 (ITT) Y Y Y 7 
Stott et al. (2013) Y CT Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 22.01 - 57.59 Y Y Y 7 
van der Helden et al. (2013) Y Y Y Y (a) Y 
(b) Y 
(a) Y 
(b) Y 
Large 46.33 - 56.09 (ITT) Y Y Y 11 
Voder et al. (2013) Y CT Y N (a) N  
(b) N 
(a) N  
(b) N 
Large 39.5 - 47.08 (ITT) Y Y Y 5 
Yuen et al. (2013) Y Y Y Y (a) Y 
(b) Y 
(a) Y 
(b) N 
Large 39.38 - 56.04 Y Y CT 9 
2012 Studies             
Tarquinio et al. (2012) Y Y N N (a) N  
(b) N 
(a) Y 
(b) N 
Large  26.41 - 32.19 N Y Y 5 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Wagner et al. (2012) Y Y CT CT (a) N 
(b) N 
(a) N 
(b) N 
Large 8.93 - 18.81 CT CT CT 2 
Wroe et al. (2012) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 12.36 - 20.18 Y Y Y 7 
2011 studies             
Alvarez et al. (2011) Y Y Y N (a) Y 
(b) Y 
(a) N 
(b) N 
Medium 53.04 - 57.96 Y Y Y 8 
Andersson et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 6.98 - 13.02 Y Y Y 9 
Ayers et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) Y 
(b) Y 
Large 18.8 - 25.7 Y Y Y 9 
Chard et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 40.7 - 57.22 Y Y N 8 
Chard et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 28.58 - 46.7 Y Y N 8 
Gros, Antony, et al. (2011) Y Y Y Y (a) N 
(b) N 
(a) N 
(b) N 
Large 16.94 - 25.26 Y Y Y 7 
Gros, Antony, et al. (2011) Y Y Y Y (a) N 
(b) N 
(a) N 
(b) N 
Large 23.39 - 34.01 Y Y CT 6 
Gros, Yoder, et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 43.03 - 52.57 Y Y Y 7 
Gros, Yoder, et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 27.64 - 35.56 Y Y Y 7 
Haraguchi et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 16.52 - 21.48 (ITT) Y Y Y 9 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Hindo et al. (2011) Y CT Y Y (a) Y 
(b) Y 
(a) Y 
(b) N 
Large 48.02 - 63.46 Y Y Y 9 
Long et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 50.72 - 60.68 Y Y Y 7 
Nakatani et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 8 - 11.6 Y Y Y 7 
Nakatani et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 9.53 - 13.07 Y Y Y 7 
Nevo et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) Y 
(b) N 
Large 9.04 - 10.96 Y Y Y 8 
Nixon et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) Y  
(b) N 
Large 32.11 - 56.09 Y Y Y 10 
Olino et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) N 
(b) N 
Large 10.98 - 11.8 Y Y Y 9 
Telch et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 14.91 - 21.25 Y Y Y 7 
Telch et al. (2011) Y Y Y Y (a) N  
(b) N 
(a) N 
(b) N 
Large 22.31 - 32.51 CT Y Y 6 
Turek et al. (2011) Y CT Y Y (a) N  
(b) Y 
(a) N 
(b) N 
Large 41.54 - 51.04 Y Y Y 6 
Westra et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) Y 
(b) Y 
Large 30.11 - 49.07 Y Y Y 11 
Westra et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) Y 
(b) Y 
Large 44.12 - 69.22 Y Y Y 11 
Westra et al. (2011) Y Y Y Y (a) Y 
(b) Y 
(a) Y 
(b) Y 
Large 25.51 - 39.49 Y Y Y 11 
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Study 1 2 3 4 5 6 7 8 (95% CI) 9 10 11 Total Yes 
Wetherall et al. (2011) Y CT Y Y (a) N  
(b) N 
(a) N 
(b) N 
Medium 4.23 - 12.17 CT CT CT 3 
Wootton et al. (2011) Y CT Y Y (a) Y 
(b) Y 
(a) Y 
(b) N 
Large 10.33 - 14.87 Y Y Y 9 
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Table 5.  
Summary of meta-analysis results for overall effect sizes 
 Efficacy 
 Completer analysis Intent-to-treat analysis 
 k ?̅?∗ SE 95% CI z k ?̅?∗ SE 95% CI z 
Pre- to post-test 41 1.37 .09 1.19 - 1.56 14.6 69 1.25 .08 1.1 - 1.40 16.43 
Pre-test to follow-up 29 1.63 .15 1.34 - 1.93 10.72 53 1.41 .08 1.24 - 1.57 16.66 
Post-test to follow-up 29 0.23 .11 .01 - .45 2.08 53 0.17 .05 .06 - .27 3.09 
 Effectiveness 
 Completer analysis Intent-to-treat analysis 
Pre- to post-test 40 1.47 .08 1.3 - 1.63 17.58 19 1.15 .14 .87 - 1.43 8.08 
Pre-test to follow-up 8 1.62 .3 1.04 - 2.2 5.47 6 1.77 .41 .97 - 2.58 4.31 
Post-test to follow-up 8 0.01 .21 -0.4 - .43 0.07 6 0.10 .18 -0.25 - .45 .057 
 OCD (pre- to post-test) 
 Completer analysis Intent-to-treat analysis 
 k ?̅?∗ SE 95% CI z k ?̅?∗ SE 95% CI z 
Efficacy 12 1.39 .2 1.0 - 1.77 7.09 13 1.72 .17 1.39 - 2.06 10.02 
Effectiveness 9 1.63 .12 .12 - 1.86 13.29 4 - - - - 
 PTSD (pre- to post-test) 
 Completer analysis Intent-to-treat analysis 
Efficacy 9 1.44 .26 .94 - 1.94 5.6 19 1.26 .12 1.03 - 1.48 10.92 
Effectiveness 18 1.40 .13 1.15 - 1.66 10.73 10 1.30 .23 .85 - 1.75 5.71 
 SAD (pre- to post-test) 
 Completer analysis Intent-to-treat analysis 
Efficacy 13 1.61 .12 .93 - 1.39 10.05 20 0.87 .11 .67 - 1.08 8.27 
Effectiveness 5 1.08 .19 .19 - .71 5.70 1 - - - - 
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Table 6. 
Moderators in the treatment of anxiety disorders 
 K ?̅?∗ SE 95% CI Subgroup 
analysis 
Exposure at Pre-/post-test     Q df p 
Efficacy – Completer     3.64 1 .056 
 With exposure 18 1.56 0.12 1.33 - 1.79    
 Without exposure 23 1.22 0.13 .96 - 1.48    
Efficacy - Intent-to-treat**     9.49 1 .002 
 With exposure 49 1.40 0.1 1.2 - 1.59    
 Without exposure 20 0.96 0.1 .75 - 1.16    
Effectiveness Completer     0.29 1 .590 
 With exposure 35 1.49 0.09 1.32 - 1.66    
 Without exposure 5 1.31 0.31 .7 - 1.92    
Completer between study types  - with exposure     .001 1 .903 
 Efficacy  18 1.56 0.12 1.33 - 1.79    
 Effectiveness 35 1.49 0.09 1.31 - 1.66    
Completer between study types - without exposure     0.07 1 .786 
 Efficacy  23 1.22 0.13 .96 - 1.48    
 Effectiveness 5 1.31 0.31 .7 - 1.92    
Intent-to-treat between study types - with exposure     2.89 1 .089 
 Efficacy  49 1.40 0.1 1.2 - 1.59    
 Effectiveness 15 1.12 0.13 .86 - 1.38    
Exposure at Pre-test to follow-up        
Efficacy – Completer     0.27 1 .603 
 With exposure 11 1.71 0.19 1.34 - 2.09    
 Without exposure 18 1.55 0.23 1.1 - 2.02    
Efficacy - Intent-to-treat     0.15 1 .698 
 With exposure 37 1.56 0.1 1.35-1.76    
 Without exposure 16 1.35 0.51 .36 - 2. 35    
Completer between study types  - with exposure     0.07 1 .792 
 Efficacy  11 1.71 0.19 1.34 - 2.09    
 Effectiveness 8 1.62 0.3 1.04 - 2.21    
Intent-to-treat between study types - with exposure     0.26 1 .613 
 Efficacy  37 1.56 0.1 1.35-1.76    
 Effectiveness 6 1.77 0.41 .97 - 2.76    
OCD (Pre-/post-test)     1.06 1 .302 
Completer between study type        
 Efficacy 12 1.39 0.2 1.0 - 1.77    
 Effectiveness 9 1.63 0.12 1.39 - 1.86    
Completer between study type with exposure     0.06 1 .800 
 Efficacy 8 1.57 .19 1.2 - 1.93    
 Effectiveness 9 1.63 0.12 1.39 - 1.86    
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 K ?̅?∗ SE 95% CI Subgroup 
analysis 
     Q df p 
PTSD (Pre-/post-test)        
Completer between study type     0.02 1 .887 
 Efficacy  9 1.44 0.26 .94 - 1.94    
 Effectiveness 18 1.4 0.13 1.15 - 1.66    
Intent-to-treat between study types     0.02 1 .899 
 Efficacy  18 1.27 0.12 1.03 – 1.51    
 Effectiveness 10 1.3 0.23 0.85 - 1.75    
Efficacy - Intent-to-treat and exposure*        
 With exposure 12 1.46 0.17 1.14 – 1.79 4.66 1 .031 
 Without exposure 6 0.94 0.18 .59 - 1.29    
Effectiveness - Completer and exposure     0.12 1 .729 
 With exposure 13 1.43 0.15 1.14 - 1.73    
 Without exposure 5 1.31 0.31 .7 - 1.92    
SAD (Pre-/post-test)        
Completer between study type     0.13 1 .714 
 Efficacy  13 1.16 0.12 .12 - 1.39    
 Effectiveness 5 1.08 0.19 .71 - 1.45    
Efficacy - Intent-to-treat and exposure     1.14 1 .285 
 With exposure 10 0.96 0.17 .63 - 1.29    
 Without exposure 10 0.74 0.12 .51 - .97    
Session Length        
Efficacy – Completer     3.81 3 .283 
 1 to 5 sessions 5 1.72 0.46 .83 - 2.61    
 6 to 10 sesions 11 1.11 0.16 .80 - 1.43    
 11 to 15 sessions 10 1.51 016 1.19 - 1.83    
 16+ Sessions 15 1.39 .15 1.11 - 1.68    
Efficacy - Intent to Treat     1.86 3 .601 
 1 to 5 sessions 13 1.57 .26 1.06 - 2.07    
 6 to 10 sesions 29 1.20 .13 .95 - 1.46    
 11 to 15 sessions 22 1.20 .09 1.01 - 1.39    
 16+ Sessions 6 1.24 .17 .89 - 1.58    
Effectivenss – Completer     2.04 1 .154 
 6 to 10 sessions 11 1.27 .15 .98 - 1.56    
 11 to 15 sessions 22 1.55 .12 1.31 - 1.78    
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 K ?̅?∗ SE 95% CI Subgroup 
analysis 
     Q df p 
Year of Publication        
Efficacy – Completer     7.59 3 .055 
 2014 5 0.83 .21 .42 – 1.23    
 2013 14 1.49 .17 1.16 – 1.82    
 2012 9 1.51 .23 1.06 – 1.96    
 2011 13 1.21 .14 .95 – 1.48    
Efficacy – Intent-to-treat     2.82 3 .420 
 2014 8 1.33 .23 .88 – 1.78    
 2013 28 1.10 .12 .85 – 1.34    
 2012 8 1.49 .28 .94 – 2.03    
 2011 25 1.31 .10 1.12 – 1.51    
Effectiveness – Completer     3.29 3 .349 
 2014 7 1.41 .25 .92 – 1.90    
 2013 11 1.31 .11 1.09 – 1.53    
 2012 3 1.72 .44 .86 – 2.57    
 2011 19 1.63 .15 1.33 – 1.92    
Effectivness – Intent-to-treat     1.55 2 .460 
 2014 2 0.60 .47 -0.32 – 1.53    
 2013 8 1.20 .22 .78 – 1.63    
 2011 9 1.24 .24 .76 – 1.72    
Difference between study types – Completer (2011)*     4.10 1 .043 
 Efficacy 13 1.21 .14 .95 – 1.48    
 Effectiveness 19 1.63 .15 1.33 – 1.92    
* p < .05 (2-tailed), ** p < .01 
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Table 7. 
Treatments and their level of empirical support. 
Disorder Treatments1 Notes 
OCD   
 Efficacious  None to add 
 
 
 Possibly efficacious  CBT (Bolton 2011) 
 
 ERP (Simpson et al. 2013) 
 
Lacks independent replication with an appropriate sample size 
 
Lacks independent replication with an appropriate sample size. 
PTSD   
 Efficacious  None to add 
 
 
 Possibly efficacious  CT/Intensive CT (Ehlers et al. 2014) 
 
 CPT (Lloyd et al. 2013) 
 
Lacks independent replication with an appropriate sample size. 
 
 
Lacks independent replication 
 
SAD   
 Efficacious  CBT (Kucketz et al., 2014; Price & 
Anderson, 2011) 
 
Supported by several other studies, that lack an appropriate sample size 
 Possibly efficacious  BST (Rakowska, 2011) 
 
 CBM (Sportel et al., 2013) 
 
 CT (Stangier et al. 2011) 
 
 MAGT (Kucketz et al., 2014) 
Lacks independent replication 
 
Lack independent replication 
 
Lack independent replication with an appropriate sample size 
 
Lacks independent replication; needs each component tested seperately. 
1 BST – Brief Strategic Therapy; CBM - Cognitive Bias Modification; CBT – Cognitive Behavioural Therapy; CT – Cognitive Therapy; ERP – 
Exposure and Ritual/Response prevention; MAGT - Mindfulness and Acceptance-Based Therapy.  
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Figure 1 
Figure 1. Flowchart of identification and selection of articles 
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Records excluded – not in English  
(n = 422) 
Records screened  
(n = 7634) 
Records excluded  
(n = 7276) 
Full-text articles assessed 
for eligibility  
(n = 358) 
Full-text articles excluded,  
(n =   259) 
Behind a paywall, n = 40 
Case study with N < 10, n = 5 
Dataset reported in another paper, n = 2 
Does not look at psychotherapy, n = 2 
Therapy undefined, n = 7 
Error identified in data, n = 5 
No empirical measures of anxiety, n = 1 
No outcome data reported, n = 9 
No manual or protocol specified, n = 17 
Anxiety disorder not 
specified/required/defined, n = 63 
Effect size could not be calculated for 
single anxiety disorder, n = 108 
 
Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 99) 
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Figure 2 
 
Figure 2A. Funnel plot for publication bias (Efficacy CA) 
 
 
Figure 2B. Funnel plot for publication bias (Efficacy ITT) 
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Figure 2C. Funnel plot for publication bias (Effectiveness CA) 
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Figure 2D. Funnel plot for publication bias (Effectiveness ITT) 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
-1.00 0.00 1.00 2.00 3.00 4.00
St
an
d
ar
d
 e
rr
o
r
Effect Size
Studies Combined Effect Size Adjusted CES Inputed Data Points
TREATMENT OF ANXIETY DISORDERS  86 
 
 
 
  
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
-2.00 0.00 2.00 4.00 6.00 8.00 10.00
St
an
d
ar
d
 e
rr
o
r
Effect Size
Studies Combined Effect Size Adjusted CES Inputed Data Points
TREATMENT OF ANXIETY DISORDERS  87 
 
Figure 3 
 
 
 
  
TREATMENT OF ANXIETY DISORDERS  88 
 
Figure 4 
 
 
 
Appendix A 
Category 1: Disorder terms 
Anxiety, anxiety disorders, generalized anxiety disorder, generalised anxiety disorder, GAD, 
post-traumatic stress disorder, post traumatic stress disorder, posttraumatic stress disorder, 
PTSD, simple phobia, phobias, social phobias, phobia, obsessive-compulsive personality 
disorder, obsessive compulsive personality disorder, OCD, panic disorders, separation 
anxiety, and situational anxiety 
 
Category 2: Therapy terms 
Therapy, therapies, treatment, treatments, cognitive behavior therapy, cognitive behaviour 
therapy, CBT, behavior therapy, behaviour therapy, behavioral therapy, behavioural therapy, 
behavioural modification, behavioral modification. 
 
Category 3: Result terms 
Results, outcome, efficacy, effectiveness, benefit, and impact. 
 
 
